

AUDITED FINANCIAL STATEMENTS,
SUPPLEMENTARY INFORMATION, AND REPORTS AND
SCHEDULES REQUIRED BY THE
UNIFORM GUIDANCE AND THE
STATE OF TEXAS SINGLE AUDIT CIRCULAR

Baylor College of Medicine
Years Ended June 30, 2020 and 2019
With Reports of Independent Auditors

Ernst & Young LLP



Baylor College of Medicine

Audited Financial Statements, Supplemental Information, and Reports
and Schedules Required by the Uniform Guidance and the
State of Texas Single Audit Circular

Years Ended June 30, 2020 and 2019

Contents

Report of Independent Auditors.....1

Audited Financial Statements

Consolidated Balance Sheets3

Consolidated Statements of Activities4

Consolidated Statements of Cash Flows.....5

Notes to Consolidated Financial Statements.....7

Supplementary Information

Financial Responsibility Supplemental Schedule52

Reports and Schedules Required by the Uniform Guidance and the
State of Texas Single Audit Circular

Report of Independent Auditors on Internal Control Over Financial Reporting and
on Compliance and Other Matters Based on an Audit of Financial Statements
Performed in Accordance with *Government Auditing Standards*55

Report of Independent Auditors on Compliance for Each Major Federal and State
Program and Report on Internal Control Over Compliance Required by the Uniform
Guidance and *State of Texas Single Audit Circular*57

Schedule of Expenditures of Federal Awards.....60

Schedule of Expenditures of State Awards.....95

Notes to Schedule of Expenditures of Federal Awards and Schedule of Expenditures
of State Awards.....103

Schedule of Findings and Questioned Costs.....106



Ernst & Young LLP
1401 McKinney Street
Suite 2400
Houston, TX 77010

Tel: +1 713 750 1500
Fax: +1 713 750 1501
ey.com

Report of Independent Auditors

Management and Board of Trustees
Baylor College of Medicine

Report on the Financial Statements

We have audited the accompanying consolidated financial statements of Baylor College of Medicine, which comprise the consolidated balance sheets as of June 30, 2020 and 2019, and the related consolidated statements of activities, and cash flows for the years then ended, and the related notes to the consolidated financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in conformity with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free of material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Baylor College of Medicine at June 30, 2020 and 2019, and the consolidated results of its operations and its cash flows for the years then ended in conformity with U.S. generally accepted accounting principles.

Adoption of ASU No. 2016-02 Leases (Topic 842)


As discussed in Note 2 to the consolidated financial statements, the College changed its method of accounting for leases as a result of the adoption of the amendments to the FASB Accounting Standards Codification resulting from Accounting Standards Update 2016-02, *Leases (Topic 842)*, effective July 1, 2019. Our opinion is not modified with respect to this matter.

Supplementary Information

Our audits were conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. We have not performed any procedures with respect to the audited consolidated financial statements subsequent to October 5, 2020. The accompanying Financial Responsibility Supplemental Schedule required by the U.S. Department of Education; the Schedule of Expenditures of Federal Awards as required by Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards*; and the Schedule of Expenditures of State Awards as required by the *State of Texas Singular Audit Circular* are presented for purposes of additional analysis and are not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States. In our opinion, the information is fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we also have issued our report dated October 5, 2020 on our consideration of Baylor College of Medicine's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of Baylor College of Medicine's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering Baylor College of Medicine's internal control over financial reporting and compliance.



October 5, 2020, except for our report on the
Schedule of Expenditures of Federal Awards and
Schedule of Expenditures of State Awards,
for which the date is March 31, 2021

Baylor College of Medicine
Consolidated Balance Sheets

	June 30	
	2020	2019
	<i>(In Thousands)</i>	
Assets		
Cash and cash equivalents	\$ 29,241	\$ 44,869
Accounts receivable, net:		
Patient	24,468	20,558
Affiliates	112,512	99,749
Grants and contracts, and others	98,384	97,499
Pledges receivable	43,826	63,838
Notes receivable	17,866	15,265
Investments, including securities loaned of \$17,089 and \$34,044 for 2020 and 2019, respectively	1,224,606	1,340,869
Equity investments in unconsolidated affiliates	320,393	358,344
Security lending collateral	17,701	34,984
Property and equipment, net	403,992	413,261
Leased right-of-use assets – operating	105,370	–
Other assets	14,484	15,024
Total assets	\$ 2,412,843	\$ 2,504,260
Liabilities and net assets		
Liabilities:		
Accounts payable and other liabilities	\$ 191,675	\$ 171,538
Short-term line of credit	45,000	26,000
Interest rate swap liability, net	105,029	66,183
Lease liability – operating	105,978	–
Self-insurance reserves	38,879	37,895
Deferred revenue	112,989	150,366
Bonds and notes payable	586,695	599,249
Assets held on behalf of others	42,106	44,694
Payable under security lending agreements	17,701	34,984
Total liabilities	1,246,052	1,130,909
Net assets:		
Without donor restrictions	358,776	434,851
With donor restrictions	808,015	938,500
Total net assets	1,166,791	1,373,351
Total liabilities and net assets	\$ 2,412,843	\$ 2,504,260

See accompanying notes.

Baylor College of Medicine

Consolidated Statements of Activities

	Year Ended June 30, 2020			Year Ended June 30, 2019		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
	<i>(In Thousands)</i>			<i>(In Thousands)</i>		
Operating revenues						
Tuition and fees, net	\$ 23,459	\$ –	\$ 23,459	\$ 20,141	\$ –	\$ 20,141
Medical services, net	293,754	–	293,754	315,421	–	315,421
Affiliated hospital contracts	1,051,860	–	1,051,860	1,035,213	–	1,035,213
Government grants and contracts:						
Direct	294,333	–	294,333	283,689	–	283,689
Indirect	83,562	–	83,562	79,734	–	79,734
Private grants and contracts:						
Direct	79,396	–	79,396	123,973	–	123,973
Indirect	9,474	–	9,474	11,405	–	11,405
Gifts and pledges	5,025	–	5,025	14,672	–	14,672
State appropriations	26,110	–	26,110	4,107	–	4,107
Investment income, net of expenses	58,586	–	58,586	56,588	–	56,588
Equity in loss of unconsolidated affiliates – operating	(18,410)	–	(18,410)	(3,092)	–	(3,092)
Equipment acquired through grants and contracts	9,668	–	9,668	11,687	–	11,687
Net assets released from restrictions	32,818	–	32,818	41,667	–	41,667
Other	117,248	–	117,248	63,235	–	63,235
Total operating revenues	2,066,883	–	2,066,883	2,058,440	–	2,058,440
Operating expenses						
Salaries, wages, and benefits	1,615,182	–	1,615,182	1,575,824	–	1,575,824
Services, supplies, and other	396,364	–	396,364	422,424	–	422,424
Depreciation	56,559	–	56,559	57,312	–	57,312
Interest	27,058	–	27,058	27,025	–	27,025
Total operating expenses	2,095,163	–	2,095,163	2,082,585	–	2,082,585
Operating expenses in excess of revenues	(28,280)	–	(28,280)	(24,145)	–	(24,145)
Nonoperating activities						
Gifts and pledges	205	12,888	13,093	86	29,329	29,415
Investment (loss) income, net of distribution and expenses	(5,533)	(110,555)	(116,088)	(23,984)	30,298	6,314
Unrealized loss on interest rate swaps	(33,236)	–	(33,236)	(20,944)	–	(20,944)
Net assets released from restrictions	–	(32,818)	(32,818)	–	(41,667)	(41,667)
Equity in loss of unconsolidated affiliates – nonoperating	(8,460)	–	(8,460)	(10,681)	–	(10,681)
Other nonoperating activities	(771)	–	(771)	(1,136)	–	(1,136)
Change in net assets from nonoperating activities	(47,795)	(130,485)	(178,280)	(56,659)	17,960	(38,699)
Change in net assets	(76,075)	(130,485)	(206,560)	(80,804)	17,960	(62,844)
Net assets, beginning of year	434,851	938,500	1,373,351	515,655	920,540	1,436,195
Net assets, end of year	\$ 358,776	\$ 808,015	\$ 1,166,791	\$ 434,851	\$ 938,500	\$ 1,373,351

See accompanying notes.

Baylor College of Medicine

Consolidated Statements of Cash Flows

	Year Ended June 30	
	2020	2019
	<i>(In Thousands)</i>	
Operating activities		
Change in net assets	\$ (206,560)	\$ (62,844)
Adjustments to reconcile change in net assets to net cash used in operating activities:		
Depreciation and loss on disposal of property and equipment and other	69,782	58,227
Equity in losses of unconsolidated affiliates, net	26,700	(1,191)
Equipment acquired through grants and contracts	(9,668)	(11,687)
Investment loss	(3,764)	(3,644)
Change in interest rate swap valuation	33,236	20,944
Net realized and unrealized losses (gains) on investments	62,649	(64,481)
Decrease in bond premium/discount and original issue costs	(2,459)	(2,770)
Change in pledges receivable	20,012	10,221
Change in accounts receivable	(17,558)	37,055
Gifts and pledges with donor restrictions	(3,732)	(16,926)
Change in other assets	540	734
Change in assets held on behalf of others	(2,588)	(2,609)
Change in accounts payable and other liabilities	(17,630)	9,204
Net cash used in operating activities	(51,040)	(29,767)
Investing activities		
Purchases of investments	(115,045)	(94,941)
Proceeds from sales of investments	120,507	161,597
Return of capital – Baylor St. Luke’s Medical Center	11,250	28,093
Purchases of property and equipment	(48,397)	(59,873)
Investment income	3,764	3,644
Issuances of notes receivable	(5,711)	(2,623)
Repayment of notes receivable	3,110	3,741
Net cash (used in) provided by investing activities	(30,522)	39,638
Financing activities		
Proceeds from line of credit, net	19,000	13,500
Repayment of bonds payable	(10,095)	(9,600)
Gifts and pledges with donor restrictions	3,732	16,926
Cash flows from financing leases	(464)	–
Net cash provided by financing activities	12,173	20,826
Net change in cash, cash equivalents, restricted cash and restricted cash equivalents	(69,389)	30,697
Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of year	150,181	119,484
Cash, cash equivalents, restricted cash, and restricted cash equivalents at end of year	\$ 80,792	\$ 150,181

Baylor College of Medicine

Consolidated Statements of Cash Flows (continued)

	Year Ended June 30	
	2020	2019
	<i>(In Thousands)</i>	
Reconciliation of cash, cash equivalents, restricted cash and restricted cash equivalents		
Cash and cash equivalents	\$ 29,241	\$ 44,869
Restricted cash and cash equivalents included in investments	50,571	98,722
Restricted cash and cash equivalents included in interest rate swap collateral	980	6,590
Cash, cash equivalents, restricted cash and restricted cash equivalents	\$ 80,792	\$ 150,181
Supplemental disclosures		
Net interest paid on bonds	\$ 29,251	\$ 28,561
Noncash investing and financing activities:		
(Decrease) increase in security lending collateral	\$ (17,283)	\$ 1,421
(Decrease) increase in payable under security lending agreement	(17,283)	1,421
Change in leased right-of-use assets – operating	1,090	–
Change in lease liability – operating	1,090	–

See accompanying notes.

Baylor College of Medicine

Notes to Consolidated Financial Statements

June 30, 2020

1. Organization

Baylor College of Medicine (the College or Baylor) is one of the leading health science universities and biomedical research institutions in the United States. Founded in 1900, Baylor owns and operates educational, research, and patient care facilities. The College is an institution comprising four separate colleges, including a medical school, a graduate school of biomedical sciences, a health professions school, and a national school of tropical medicine. Baylor trains more than 3,500 medical, graduate, nurse anesthesia, physician assistant, orthotics and prosthetics, and genetics counseling students, as well as residents and postdoctoral fellows each year. The College ranks among the nation's top biomedical research institutions and the country's top medical schools. Finally, the College provides extensive patient care services through its wholly owned Baylor Medicine Clinic and through faculty physician service agreements primarily with eight independently owned and operated affiliated hospitals including Baylor St. Luke's Medical Center; see description below.

Baylor's main campus is located in the Texas Medical Center, a 700-acre complex of approximately 50 independent institutions and state instrumentalities in Houston, Texas. The College is the only private medical school in the southwestern United States.

Effective January 1, 2014, St. Luke's Health System Corporation (n/k/a CHI St. Luke's Health), a Texas nonprofit corporation exempt from federal income tax under Section 501(a) of the Internal Revenue Code of 1986, as amended (the Code), as an organization described in Section 501(c)(3) of the Code, conveyed to the College a 35% membership interest in St. Luke's Medical Center (n/k/a CHI St. Luke's Health Baylor College of Medicine Medical Center), a Texas nonprofit corporation exempt from federal income tax under Section 501(a) of the Code, as an organization described in Section 501(c)(3) of the Code. CHI St. Luke's Health retained a 65% membership interest in CHI St. Luke's Health Baylor College of Medicine Medical Center (BSLMC), which owns and operates a quaternary care hospital in the Texas Medical Center; other land and improvements in and near the Texas Medical Center; and ambulatory clinics located in the Texas Medical Center area, Tanglewood, and Pearland. As consideration, the College contributed to BSLMC cash, certain real property, and improvements, including a portion of the real property generally known as the McNair Campus; the hospital/clinic building located on the McNair Campus (except for a portion of the top five floors to be used for the College's clinical operations and a conference center on the first floor); and, effective February 16, 2015, the ambulatory surgery center located in the Lee and Joe Jamail Specialty Care Center. BSLMC sold the O'Quinn Medical Tower in 2016. The College and CHI St. Luke's Health share governance of BSLMC: each member appoints, and has the unilateral ability to remove, six voting board members and one nonvoting board member. Doing business under the name Baylor St. Luke's Medical Center, the hospital serves as the home of most of the College's medical doctors dedicated to caring for private adult inpatients.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

1. Organization (continued)

Effective February 2, 2015, the College formed a joint venture with Miraca Holdings Inc. (Miraca), a company based in Tokyo, Japan, and traded on the Tokyo Stock Exchange. Miraca is dedicated to in vitro diagnostic, clinical laboratory testing, and other health-care-related businesses through its subsidiaries, such as Fujirebio Inc., one of the major Japanese domestic in vitro diagnostic reagent manufacturers, and SRL, Inc., the largest clinical laboratory testing company in Japan. Under the agreement, the College contributed its clinical genetics diagnostic laboratories business (including leases, equipment, receivables, other contracts, and certain employees) into a subsidiary company and conveyed a 60% membership interest in the subsidiary to a Miraca affiliate for \$135.9 million in cash. The College retained a 40% membership interest. The College and the Miraca affiliate share governance of the joint venture, called Baylor Miraca Genetics Laboratories, LLC (Baylor Genetics), a Texas limited liability company, and the College retained certain approval rights over aspects of Baylor Genetics that relate to the College's mission.

2. Summary of Significant Accounting Policies

Basis of Accounting and Reporting

The accompanying consolidated financial statements of Baylor have been prepared in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP). The accompanying consolidated financial statements include the accounts of all entities in which Baylor has a significant financial interest and over which Baylor has control. All intercompany accounts and transactions have been eliminated upon consolidation. Baylor Medical Foundation (the Foundation) is consolidated in the College's consolidated financial statements. The Foundation is a Texas nonprofit corporation organized exclusively to aid, support, and maintain the College through contributions received from third-party donors. Baylor's membership interests in BSLMC and Baylor Genetics are included in the College's consolidated financial statements as equity method investments.

Baylor College of Medicine International Pediatric AIDS Initiative (BIPAI) is a Texas nonprofit corporation organized to foster international HIV/AIDS prevention, care, and treatment; health professional education; and clinical research. Beginning July 1, 2019, the board governance of BIPAI's nine nongovernmental organizations was restructured to comply with certain funding eligibility criteria. The criteria requires board control to be held locally within the organization's country, thereby removing control from the College. As a result of this loss of control, the College deconsolidated the financial statement activity of the BIPAI organizations for the period ended June 30, 2020, resulting in the removal of net assets of \$2.5 million. For the period ended June 30, 2019, the BIPAI organizations contributed \$0.9 million of expenses in excess of earnings.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

Based on the existence or absence of donor-imposed restrictions, Baylor classifies resources into two categories: net assets without donor restrictions and net assets with donor restrictions.

Net assets without donor restrictions are free of donor-imposed restrictions. All revenues, gains, and losses that are not restricted by donors are included in this classification. All expenditures are reported in the without donor restrictions category since the use of restricted gifts and pledges in accordance with donors' stipulations results in the release of the restriction. Net assets without donor restrictions may be designated for specific purposes by the College's Board of Trustees.

Net assets with donor restrictions are subject to donor-imposed restrictions. Some donor-imposed restrictions expire with the passage of time or can be satisfied by action of the College. Other donor-imposed restrictions are perpetual in nature. These net assets may include unconditional pledges, interests in trusts held by others, accumulated appreciation on donor-restricted endowments that have not yet been appropriated by the Board of Trustees for distribution and donor-restricted endowments (at historical value). Generally, the donors of these assets permit the College to use a portion of the income earned on related investments for specific purposes.

Expirations of donor-imposed restrictions on net assets (i.e., the passage of time along with the annual board approval of the endowment spending rate and/or fulfilling donor-imposed stipulations) are reported as net assets released from restrictions between the applicable classes of net assets on the consolidated statement of activities. Net assets with donor-imposed restrictions related to the purchase or construction of property and equipment are released when the property or equipment is placed in service, unless donor stipulations limit the use of the assets for a period of time or for a particular purpose.

Net assets with donor restrictions as of June 30, 2020 and 2019, are principally restricted for research and education.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses during the reporting period, as well as the disclosure of contingent assets and liabilities. Actual results ultimately could differ from management's estimates and assumptions.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

Cash Equivalents

Cash and cash equivalents are liquid assets with minimal interest rate risk and original maturities of three months or less when purchased. Such assets, reported at fair value, primarily consist of depository account balances, money market funds, and short-term U.S. treasury securities. Cash held by bond trustee is reported with cash and cash equivalents.

Restricted cash and cash equivalents represent amounts set aside for long term investments or posted as collateral as required by interest rate swap agreements. These amounts are included in investments, including securities loaned and interest rate swap liability, net on the consolidated balance sheets.

Patient Receivables

Patient receivables are reported at the amount that reflects the consideration to which the College expects to be entitled in exchange for providing physician health care services. Patient receivables include discounts for contractual, implicit price concession and charity adjustments and are recorded on an accrual basis at net realizable value on the consolidated balance sheets. The estimates of implicit price concessions for patient receivables are based primarily on the aging of the receivables and the College's historical collection and write-off experience (see Note 4).

Affiliate Receivables

Affiliate receivables consist of amounts owed by various affiliated hospitals to which the College provides medical, professional, and supervisory staff to deliver patient care, teaching, and staff leadership services. These receivables are recorded on an accrual basis at net realizable value on the consolidated balance sheets.

Grants and Contracts, and other Receivable

Grants and contracts, and other receivable primarily represent unreimbursed grant and contract expenditures from the federal government, principally the National Institutes of Health, and other nonfederal sources for payment for research provided by the College. These amounts are recorded on an accrual basis at net realizable value on the consolidated balance sheets.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

Pledges Receivable

Unconditional promises to give that are expected to be collected within one year are recorded at net realizable value. Unconditional promises to give that are expected to be collected in future years are recorded at fair value, which is measured as the present value of their future cash flows. The discounts on those amounts are computed using risk-adjusted interest rates applicable to the years in which the promises are received. Amortization of the discounts is included in gifts and pledges revenue.

An allowance is made for uncollectible pledges receivable based upon the College's analysis of past collection experience and other judgmental factors.

Investments

The College's investments in marketable equity and fixed-income securities are recorded at fair value. Non-marketable securities are securities for which no public market exists; substantially all of these securities are accounted for at fair value using the practical expedient of net asset value per share or the equivalent. These non-marketable securities include investments in private equity limited liability corporations or partnerships. Other investments are stated at cost or fair value at the date of the acquisition or donation.

Realized gains and losses arising from the sale or other disposition of investments have been accounted for as changes in net assets without donor restrictions unless restrictions have been imposed by the donor. Certain investments are pooled with each fund subscribing to or disposing of units on the basis of the market value per unit, which is computed monthly. Realized gains and losses arising from the sale of securities are determined on an average cost basis.

The College's intent is to maintain a long-term investment portfolio to support research, education, and other activities. Accordingly, the total investment return is reported in the consolidated statements of activities in two categories. The investment return allocated to operating activities is determined by a formula, which involves allocating 5% of a trailing 28-quarter average market value of the endowment assets. Management believes this return is approximately equal to the real return the College expects to earn on its investments over the long term. The unallocated investment return, included in non-operating activities in the consolidated statements of activities, represents the difference between the total investment return and the amount allocated to operating activities, net of investment costs.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

Securities Lending

The College participates in securities lending transactions whereby a portion of its investments is loaned, through its agent, to various parties in return for cash and securities from the parties as collateral for the securities loaned, usually on a short-term basis. Collateral provided by parties is maintained at levels of at least 100% of the fair value of the securities on loan and is adjusted for market fluctuations. The fees received for these transactions are recorded as investment income.

Property and Equipment

Purchased property, plant, and equipment are recorded at cost, including, where appropriate, capitalized interest and software costs. Donated assets are recorded at fair value at the date of donation. Repairs and maintenance costs are expensed as incurred. Depreciation is calculated using the straight-line method to allocate the cost of various classes of assets over their estimated useful lives. Property, plant, and equipment are removed from the accounting records at the time of disposal.

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment charge is recognized when the fair value of the asset or group of assets is less than the carrying value.

Deferred Revenue

Deferred revenue consists of amounts received from grant and contract sponsors, affiliated hospitals, and others for which the College has not yet fulfilled its obligations. These amounts will be recognized in future periods to support the College's medical, education, and research missions once the obligations have been satisfied.

Assets Held on Behalf of Others

The College holds assets received from others and agrees to use those assets on behalf of or transfer the assets, return on investment of the assets, or both to a specified beneficiary. For the years ended June 30, 2020 and 2019, pooled investments in the amount of \$31.1 million and \$34.0 million, respectively, were held on behalf of the state of Texas (see Note 6). The College also held funds associated with a cooperative agreement with the federal government in the amount of \$11.0 million and \$10.7 million for the years ended June 30, 2020 and 2019, respectively. These funds are appropriated for the use of a federal government facility.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

Fair Value Measurements

Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, *Fair Value Measurement*, defines fair value, requires expanded disclosures about fair value measurements, and establishes a three-level hierarchy for fair value measurements based on the observable inputs to the valuation of an asset or liability at the measurement date. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (exit price) in an orderly transaction between market participants at the measurement date. ASC 820 prioritizes the inputs to the valuation techniques used to measure fair value by giving the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements).

Furthermore, ASC 820 applies to certain investment funds that do not have readily determinable fair values, including private investments, hedge funds, real estate, and other funds. ASC 820 allows for the estimation of the fair value of investments in investment companies for which the investment does not have a readily determinable fair value using net asset value per share or its equivalent. See Note 12 for further discussion of fair value measurement.

Debt Portfolio Financial Instruments

Long-term debt is reported at carrying value. The College employs derivatives in the form of fixed payor swaps, primarily interest rate exchange agreements, to help manage interest rate risks associated with variable rate debt. Derivative financial instruments are reported at fair value with any resulting gain or loss recognized as a nonoperating item on the consolidated statements of activities. Periodic net cash settlement amounts with counterparties are accounted for as adjustments to interest expense on the related debt.

Parties to interest rate exchange agreements are subject to risk for changes in interest rates, as well as risk of credit loss in the event of nonperformance by the counterparty. Baylor deals only with high-quality counterparties that meet rating criteria for financial stability and creditworthiness. Additionally, certain agreements require the posting of collateral when amounts subject to credit risk under the contracts exceed specified levels. Collateral levels are tied to the College's credit rating. The College records its interest rate swap liability net of collateral posted.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

Operating Results

Operating results are broadly defined as changes in net assets without donor restrictions from operating activities and are reported as operating expenses in excess of revenues on the consolidated statements of activities. Net assets without donor restrictions are also affected by nonoperating activities, which include gains on formation of joint ventures; equity in earnings or losses that are not integral to operations; investment income/loss and other, net of distributions; change in the fair value of interest rate swap agreements; gifts and pledges for plant facilities; and certain other nonrecurring items.

Charity Care

The College is committed to providing assistance to financially indigent patients in the community who require care and services at reduced or no cost, as determined by its affiliated hospitals. Records are maintained to identify and monitor the level of charity care the College provides. These records include the amount of charges forgone and estimated costs for services and supplies furnished under its charity care policy. Costs incurred are estimated based on a Medicare cost factor applied to total gross charges for indigent patients after reducing costs for any payments received. The level of charity care provided, based on estimated costs, during fiscal years 2020 and 2019 was \$62.3 million and \$60.4 million, respectively.

Endowment Investments and Income Distribution

The College's investments are managed to achieve the maximum long-term return. Operating investment income distribution and other consists of amounts distributed from the College's endowment funds and from income on operating investments. The amount distributed from the endowment funds to support current operations is determined by the Board of Trustees and is based on a 5% distribution rate applied to a trailing 28-quarter average market value of the endowment portfolio. The Board of Trustees may, in its discretion, designate additional funds to be used for operating purposes. The primary objective of the 5% endowment distribution methodology is to reduce the impact of capital market fluctuations on operational programs. Nonoperating investment income (loss) consists of dividends, interest, and realized and unrealized gains and losses on endowed investments, net of distribution to operations and investment expenses.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

Leases

Effective July 1, 2019, the College adopted the provisions of ASU 2016-02, *Leases (Topic 842)*. ASU 2016-02 requires lessees to recognize a right-of-use (ROU) asset and related lease liability representing the obligation to make lease payments for certain lease transactions on the consolidated balance sheets as well as disclose additional information.

The College leases various equipment and facilities, including office space. Operating and financing leases with an initial term greater than twelve months are recognized as ROU assets and lease liabilities on the consolidated balance sheets. Financing ROU assets and liabilities are reported as part of Property and equipment, net and Accounts payable and other liabilities, respectively. ROU assets and related liabilities are recognized on the commencement date on the consolidated balance sheets based on future lease payments, and discounted based on the applicable risk-free interest rate, as permitted under the standard for non-public business entities.

Lease payments under certain agreements may escalate over the lease term either by a fixed percentage or a fixed dollar amount. Certain leases may provide for variable lease payments in the form of payments based on index-based (e.g., the U.S. Consumer Price Index) adjustments to lease payments. Baylor's lease terms may include options to extend or terminate the lease. Such options are included in the measurement of the ROU asset and liability, provided the existence of reasonable assurance that the College will exercise the option. The College has no leases which contain residual value guarantees provided by the College as a lessee.

In transition to ASC 842, the College elected to apply the effective date transition method as of the July 1, 2019 adoption date. In accordance with this method, Baylor's reporting for comparative periods prior to July 1, 2019 presented in the financial statements continues to be in conformity with the guidance in ASC 840.

Income Taxes

The College is a tax-exempt organization as described in Section 501(c)(3) of the Code and is generally exempt from federal income taxes on related income pursuant to Section 501(a) of the Code. Baylor is, however, subject to federal and state income tax on unrelated business income and files unrelated business income tax and other information returns as required by government authorities. Management annually reviews its tax positions and has determined that there are no material uncertain tax positions that require recognition on the accompanying consolidated balance sheets as of June 30, 2020 or 2019.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

The Tax Cuts and Jobs Act (the TCJA) was enacted on December 22, 2017. For tax-exempt entities, the TCJA requires organizations to pay excise tax on compensation and net investment income after meeting certain thresholds and record income or losses from unrelated business activities on an activity-by-activity basis, among other provisions. As of and for the year ended June 30, 2020, the College has followed proposed regulations and made reasonable estimates of the provision for income taxes; the compensation excise tax; and the effects, if any, on existing deferred tax balances based on accounting guidance included in ASC 740, *Income Taxes*.

The College will continue to refine its calculations in future periods, as additional regulations and guidance are issued by the IRS.

COVID-19

On March 11, 2020, the World Health Organization designated COVID-19 as a global pandemic. Clinical patient volumes, research activities, and related revenue of these services were most significantly impacted beginning in mid-March 2020 as various policies were implemented by federal, state and local governments in response to the COVID-19 pandemic, including stay-at-home orders, business closures, social distancing and suspension of elective and nonemergent procedures. The College's Education and Public Services missions were less impacted financially from the pandemic. In early May, certain of these policies, such as stay-at-home orders were lifted and the College experienced gradual improvement in volumes and related revenue from both the clinical and research areas. During this time the College has also experienced supply chain disruptions, including significant price increases in medical supplies, particularly personal protective equipment. In addition, the pandemic has created significant volatility in the U.S. and global financial markets that has impacted the College's investment portfolio, but has gradually improved in the fourth quarter of the College's 2020 fiscal year.

The Coronavirus Aid, Relief, and Economic Security Act (CARES Act), was enacted on March 27, 2020, to provide funding to organizations who experienced lost revenues due to the pandemic. This funding provided a source of pandemic relief for the College to recover lost revenues. In response to the CARES Act pronouncement, the College took action to quantify and assess the lost clinical revenues for the periods of March and April, and submitted a total claim of \$20.2 million on June 2, 2020 under the Provider Relief Fund. The College received \$3.5 million during the last quarter of fiscal year 2020 as part of the lost revenue claim submission, and recorded \$3.4 million as Other revenues in the statement of activities for the year ended June 30, 2020.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

In July 2020, the College received the remaining \$16.6 million of the total lost revenues claim. The College will continue to assess the availability and eligibility of additional funding resources under all available programs under the CARES Act.

The CARES Act also included the Education Stabilization Funds, which appropriated \$14.0 billion to the Higher Education Emergency Relief Fund (HEERF). In June 2020, \$0.5 million of HEERF was available to Baylor to draw down eligible expenses to aid students with the cost of attendance. As of June 30, 2020, no funds were drawn by the College.

In addition to the above, the College is also applying for reimbursement for qualifying expenses under the Federal Emergency Management Agency Disaster Relief Fund. Due to the evolving nature of the COVID-19 pandemic, the ultimate impact to the College and its financial condition is currently unknown.

The College took additional measures to improve its liquidity. Beginning March 2020, the College began deferring the employer's portion of payroll taxes allowed under CARES Act section 2302. As of June 30, 2020, the College deferred \$13.6 million of these taxes and recorded in Accounts payable and other liabilities. In April 2020, the College extended its revolving credit facility. See Note 10 for discussion of the College's credit facility.

Subsequent Events

The College evaluated events and transactions occurring subsequent to June 30, 2020 through October 5, 2020, the date the accompanying consolidated financial statements were issued. During this period, there were no subsequent events that required recognition in the accompanying consolidated financial statements, nor were there any additional nonrecognized subsequent events that require disclosure, other than described under COVID-19.

Adopted Accounting Pronouncements

In February 2016, the FASB issued ASU 2016-02, *Leases (Topic 842)*. ASU 2016-02 requires companies that lease assets to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, on its balance sheet. The pronouncement also requires additional disclosures about the amount, timing, and uncertainty of cash flows arising from leases.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

The provisions of ASU 2016-02 were effective for the College starting July 1, 2019, including interim periods within that reporting period. The College elected the following practical expedients, which allow an entity to:

- Not reassess whether any contracts that existed prior to the July 1, 2019 implementation date are or contain leases;
- Not reassess the lease classification for any leases that commenced prior to the implementation date, meaning that all commenced capital leases under ASC 840 will be classified as finance leases under ASC 842 and all commenced operating leases under ASC 840 will be classified as operating leases under ASC 842;
- Not reassess initial direct costs for any leases;
- Not separate lease and non-lease components, except office space leases

The primary impact of adopting the new standard was the recognition of additional lease liabilities and corresponding right-of-use assets for leases currently classified as operating leases. As of July 1, 2019, the College recorded \$110.1 million of right of use assets, and \$110.1 million of lease liabilities recorded for leases classified as operating leases. The College adopted ASU 2016-02 effective July 1, 2019 by applying a modified retrospective approach in which comparable prior period information and disclosures were not adjusted. See accounting policy for leases herein Note 2.

In November 2016, the FASB issued ASU 2016-18, *Statement of Cash Flows (Topic 230): Restricted Cash*. The amendments in the ASU requires a statement of cash flows to explain the change during the period in the total of cash, cash equivalents, and restricted cash or cash equivalents. Entities are required to disclose the nature of the restrictions and reconcile the totals in the statement of cash flows to cash, cash equivalents, restricted cash, and restricted cash equivalents on the balance sheet when these are shown in more than one line item. The College adopted the provisions of ASU 2016-18 effective July 1, 2019 by applying a retrospective transition method, which required a restatement of its consolidated statement of cash flows for all periods presented. The effect of the new standard was to increase the amounts included in cash, cash equivalents and restricted cash and cash equivalents on the consolidated statement of cash flows by \$51.6 million, \$105.3 million and \$89.5 million at June 30, 2020, June 30, 2019 and July 1, 2019, respectively.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

3. Equity Investments in Unconsolidated Affiliates

The College has a 35% membership interest in BSLMC, which operates as a tax-exempt entity described in Section 501(c)(3) of the Code. The College's investment in BSLMC, which is accounted for under the equity method, was \$272.1 million and \$301.9 million at June 30, 2020 and 2019, respectively. The College recorded a loss from its investment in BSLMC in fiscal years 2020 and 2019 of \$18.5 million and \$3.2 million, respectively. The College received cash distributions from BSLMC totaling \$11.3 million and \$13.1 million in fiscal years 2020 and 2019, respectively. A summary of BSLMC's reported total assets, liabilities, and net assets at June 30 is as follows (in thousands):

	2020	2019
Total assets	\$ 1,068,927	\$ 1,035,155
Total liabilities	\$ 191,460	\$ 104,515
Total net assets	877,467	930,640
Total liabilities and net assets	\$ 1,068,927	\$ 1,035,155

A summary of BSLMC's reported revenues, expenses, and net income for the years ended June 30 is as follows (in thousands):

	2020	2019
Revenue	\$ 952,835	\$ 936,088
Expenses	(1,005,239)	(956,479)
Operating loss	(52,404)	(20,391)
Nonoperating income	6,913	11,359
Deficit of revenues over expenses	\$ (45,491)	\$ (9,032)

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

3. Equity Investments in Unconsolidated Affiliates (continued)

The College has a 40% membership interest in Baylor Genetics, which operates as a Texas limited liability company. The College's investment in Baylor Genetics, which is accounted for under the equity method, was \$46.1 million and \$54.4 million at June 30, 2020 and 2019, respectively. The College recorded a loss from its investment in Baylor Genetics in fiscal years 2020 and 2019 of \$8.5 million and \$10.7 million, respectively. A summary of Baylor Genetics' reported total assets, liabilities, and shareholder's equity at June 30 is as follows (in thousands):

	<u>2020</u>	<u>2019</u>
Total assets	\$ 22,652	\$ 23,575
Total liabilities	\$ 46,312	\$ 26,316
Total shareholder's deficit	(23,660)	(2,741)
Total liabilities and shareholder's deficit	\$ 22,652	\$ 23,575

A summary of Baylor Genetics' reported revenues, expenses, and net loss for the years ended June 30 is as follows (in thousands):

	<u>2020</u>	<u>2019</u>
Revenues	\$ 29,918	\$ 32,104
Expenses	(51,006)	(58,808)
Net loss	\$ (21,088)	\$ (26,704)

4. Revenue Recognition

ASC 606, Revenue From Contracts with Customers

Revenue is recognized when control of the promised services is transferred to the customers (students, patients, affiliated hospitals, and governmental entities) in an amount that reflects the consideration the College is entitled to receive in exchange for those services.

The timing of billings, cash collections, and revenue recognition results in accounts receivable and deferred revenue on the consolidated balance sheets. Receivables are recognized only to the extent that it is probable that the College will collect substantially all of the consideration to which the College is entitled in exchange for the services that will be transferred to the customer.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

4. Revenue Recognition (continued)

Tuition and Fees, Net

The performance obligation for tuition and fees, net relates to the training or educating of undergraduate medical, research graduate, and health profession students. Revenue is recognized ratably as services are rendered during the academic semester using the input method based on time elapsed over the academic semester.

The transaction price is the price of tuition net of scholarships, applicable discounts, and refunds.

The College's academic year is consistent with its fiscal year in which students are billed at the beginning of each semester within the fiscal period and payment is due before the semester ends, also within the fiscal period. The College does not receive advance payments from students prior to the start of the fiscal period. No accounts receivable or deferred liabilities related to tuition and fees were recorded within the accompanying consolidated balance sheets as of June 30, 2020 or 2019.

Medical Services, Net

Medical services, net consist of physician health care services in health care facilities, which include inpatient, outpatient, and ambulatory care facilities; physician practices; and other sites. Performance obligations include individual medical services provided to patients in both an inpatient and outpatient setting. Inpatient services are satisfied over time from patient admission to the point when services are no longer required, which is generally at the time of discharge. The inpatient medical services are recognized utilizing the input method of measuring progress, which is based on actual charges incurred. Outpatient services are satisfied at a point in time and revenue is recognized when control of services is transferred. The College believes this method provides a fair depiction of the transfer of services over the term of performance obligations based on the inputs needed to satisfy the obligations. These services are considered to be a single performance obligation.

Because all of its performance obligations relate to contracts with a duration of less than one year, the College has elected to apply the optional exemption provided in Topic 606 and, therefore, is not required to disclose the aggregate amount of transaction price allocated to medical services performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

4. Revenue Recognition (continued)

period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

The College uses a portfolio approach to account for categories of patient contracts as a collective group rather than recognizing revenue on an individual contract basis. The portfolios consist of major payor classes. Based on the historical collection trends and other analyses, the College believes that revenue recognized by utilizing the portfolio approach approximates the revenue that would have been recognized if an individual contract approach were used.

The College determines the transaction price of medical services revenue, which involves significant estimates and judgment, based on standard charges for goods and services provided, reduced by explicit and implicit price concessions, including contractual adjustments provided to commercial insurance carriers, health care maintenance organizations, and preferred provider organizations; discounts provided to uninsured and underinsured patients in accordance with policy; and/or implicit price concessions based on the historical collection experience of patient accounts. The majority of what historically was classified as provision for doubtful accounts is now treated as an implicit price concession factored into net medical service revenues.

In addition, the College determines the transaction price associated with services provided to patients who have third-party payor coverage with Medicare and Medicaid based on reimbursement terms per contractual agreements, discount policies, and historical experience.

Laws and regulations governing Medicare and Medicaid programs are complex and subject to interpretation. The College believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing. While no such regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and exclusion from the Medicare and Medicaid programs. Changes in the Medicare and Medicaid programs could have a material adverse or positive impact on prospective medical services revenues.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

4. Revenue Recognition (continued)

Management has determined that the nature, amount, timing, and uncertainty of revenue and cash flows are affected by the payors. The composition of medical service revenue by payor was as follows (in thousands):

	2020	2019
Managed care	\$ 91,067	\$ 97,482
Medicare	66,704	76,218
Medicaid	52,193	59,482
Self-pay	7,359	9,999
Other	76,431	72,240
	\$ 293,754	\$ 315,421

The composition of patient receivables (net of contractual allowance and implicit price concession) by payor at June 30 was as follows:

	Patient Receivables	
	2020	2019
Managed care	66.1%	61.9%
Medicare	16.8	18.8
Medicaid	12.6	14.8
Self-pay	2.4	2.1
Other	2.1	2.4
	100.0%	100.0%

Affiliated Hospital Contracts

The College has affiliation agreements with hospitals, including, but not limited to, Texas Children's, Harris Health (formerly Harris County Hospital District), Baylor St. Luke's Medical Center, Michael E. DeBakey Veterans Affairs Medical Center, The Methodist Hospital, The Menninger Clinic, MD Anderson Cancer Center, Children's Hospital of San Antonio, and The Institute for Rehabilitation and Research. Under the terms of these agreements, the College conducts administrative, research, and educational activities on behalf of these hospitals.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

4. Revenue Recognition (continued)

The College provides residents to the affiliated institutions; the residents in turn, provide patient care services as part of their medical training. The College satisfies this performance obligation over time as the hospitals receive the benefit of professional services. Affiliated hospital contract revenue is recognized as time elapses for actual personnel and operating costs incurred less collections that are received by the College from patient payors.

Amounts are billed periodically in accordance with agreed-upon contractual terms. The timing of revenue recognition, billings, and cash collections results in billed and unbilled receivables and customer advances and deposits on the consolidated balance sheet. These assets and liabilities are reported on the consolidated balance sheet on a contract-by-contract basis at the end of each reporting period. Affiliate receivables in the amount of \$112.5 million and \$99.7 million, were recorded as of June 30, 2020 and 2019, respectively. Affiliate deferred revenue in the amount of \$8.8 million is included on the accompanying consolidated balance sheets as of June 30, 2020 and 2019.

Following were the affiliates that accounted for greater than 10% of total affiliated contract revenue for the years ended June 30:

	<u>2020</u>	<u>2019</u>
BSLMC	17.6%	16.2%
Harris Health	16.6	16.3
Texas Children's	51.1	50.6

Following were the affiliates that accounted for greater than 10% of total affiliated contract receivables as of June 30:

	<u>2020</u>	<u>2019</u>
BSLMC	31.8%	25.8%
Texas Children's	46.6	53.5

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

4. Revenue Recognition (continued)

Other

Other revenue primarily consists of several other exchange contracts including academic program fees from our affiliates, royalties on certain licenses of intellectual property and Baylor College of Medicine brand, and various other types of income. Depending on the program, revenue is recognized at a point in time or over time as obligations are met.

In January 2020, the College recognized \$51.1 million of royalty income in consideration for an exclusive license agreement of Baylor intellectual property. In June 2020, the College recognized CARES Act funding (see Note 2).

ASC 958-605, Not-for-Profit Entities – Revenue Recognition

State appropriations – The College received funding in the form of appropriations from the State of Texas Higher Education Coordinating Board (the Coordinating Board) for the purpose of training or educating Texas resident undergraduate medical students and graduate medical resident in the amount of \$26.1 million and \$4.1 million in 2020 and 2019, respectively. The College expended \$231.0 million and \$219.3 million for fiscal years 2020 and 2019, respectively, to train and educate undergraduate medical students and graduate medical residents. Expenditures used to satisfy these appropriations are reflected on the schedule of functional expenses (see Note 13) as instruction expenditures and certain amounts related to the instruction of graduate medical residents that are included in affiliated hospital programs expenditures.

The Coordinating Board has approved the transfer of the College's state funding to the Texas Health and Human Services Commission for state fiscal years 2020 and 2019. The purpose of this intergovernmental transfer is to allow the use of the College's state funding to draw down federal dollars under the Section 1115 Medicaid Waiver Program (1115 Waiver).

Because this is a hospital-based program, the College has signed agreements to collaborate with Texas Children's, Houston Methodist Hospital, and CHI St. Luke's Health, pursuant to which these affiliates will transfer to the College the amounts the College normally would receive from the Coordinating Board. All agreements include a provision that the original appropriation will be returned to the College if the federal match anticipated under the 1115 Waiver does not occur. Amounts under these arrangements are recognized as affiliated hospital contracts, of which the College recognized \$20.4 million and \$42.1 million during the years ended June 30, 2020 and 2019, respectively.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

4. Revenue Recognition (continued)

Government and private grants and contracts – Government and private grants and contracts represent revenue from grants and contracts with federal, state, and local governments; private foundations; and corporate sponsors primarily for research and education activities conducted by the College. Direct recoveries are recognized when allowable direct expenditures for salaries and supplies are incurred under the terms of each sponsor’s agreement. Indirect recoveries represent reimbursement of the costs of facilities and administrative (F&A) overhead associated with government and private grants and contracts. Indirect recoveries are recognized as revenue as the corresponding allowable direct grant and contract expenses are incurred under the terms of each sponsor’s agreement. Baylor’s federal F&A costs recovery rate for on-campus research was 60.0% and 58.5% in fiscal years 2020 and 2019, respectively. Baylor’s federal F&A costs recovery rate for off-campus research was 26.0% in both fiscal years 2020 and 2019.

Gifts and pledges – As pledges are made to the College, the intent of the donor, circumstances surrounding the pledge, and any action taken by the College in response to the pledge are considered in determining whether the pledge is an unconditional promise to give or a conditional promise. Unconditional promises to give (pledges) are recognized as revenue without donor restrictions when the donor’s commitment is received. Gifts and pledges with donor-imposed restrictions are recorded as revenue without donor restrictions if those restrictions are met in the same reporting period. Otherwise, gifts and pledges with donor-imposed restrictions are recorded as increases in net assets with donor restrictions.

Conditional promises (primarily bequest intentions) are not recorded until donor conditions are substantially met.

Gifts and pledges recorded as donor-restricted net assets are released from restrictions and recognized as net assets without restrictions after any donor stipulations are met. Gifts and pledges for plant facilities are released from restrictions and recognized as a nonoperating item only after resources are expended for the applicable plant facilities.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

5. Pledges Receivable

Pledges receivable as of June 30 are expected to be realized as follows (in thousands):

	2020	2019
In one year or less	\$ 23,857	\$ 36,077
Between one year and five years	14,721	23,903
More than five years	11,600	12,050
Less present value discount	(6,352)	(8,192)
Total	\$ 43,826	\$ 63,838

Included in pledges receivable at June 30, 2020 and 2019, is \$6.5 million and \$7.6 million, respectively, for BSLMC. As of June 30, 2020 and 2019, the College had received conditional promises to give and indications of intentions to give of approximately \$29.6 million and \$1.0 million, respectively, in addition to the amounts recorded as pledges receivable. These conditional promises to give will be recognized in the accompanying consolidated financial statements in the periods in which the conditions are substantially met.

6. Investments

Investments (including amounts for self-insurance) held by the College at June 30 are as follows (in thousands):

	2020	2019
Pooled investments:		
Stocks	\$ 423,198	\$ 433,330
Bonds	97,083	108,517
Other short-term investments	50,571	98,722
International equities	287,343	314,292
Private equity securities	348,384	359,095
Total pooled investments	1,206,579	1,313,956
Other stocks	5,889	16,183
Real estate, at cost	2,656	2,656
Assets held in trust and other	9,482	8,074
Total investments	\$ 1,224,606	\$ 1,340,869

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

6. Investments (continued)

In fiscal year 2000, the College received \$25.0 million to establish a fund for investing a portion of receipts paid to the state of Texas under a judgment rendered in the tobacco settlement (the tobacco funds). The College is responsible for the administration of the tobacco funds, which are invested along with the College's pooled investments; however, the College does not have title to the assets. As of June 30, 2020 and 2019, the value of the tobacco funds is included in pooled investments and a corresponding liability has been recorded in Assets held on behalf of others to reflect that the College does not currently have an ownership interest.

The earnings of the tobacco funds are required to be remitted to the state of Texas, which, in turn, appropriates the earnings to the College to benefit programs in medical research, health education, and treatment. This distribution is included in state appropriations on the consolidated statements of activities.

The U.S. and international financial markets have experienced significant volatility that has resulted in substantial fluctuations in equity markets in which the College invests. Market volatility can affect the value the College receives for its investments in future periods.

Investment performance for the years ended June 30 is summarized as follows (in thousands):

	2020			
	Operating	Nonoperating	With Donor Restrictions	Total
Distribution of endowment earnings and other	\$ 924	\$ –	\$ 8	\$ 932
Net realized gains	4,082	45,415	1,937	51,434
Net unrealized gains (losses)	–	11,208	(112,682)	(101,474)
Total investment return	5,006	56,623	(110,737)	(49,108)
Investment return, designated for current operations	56,550	(56,732)	182	–
Investment management fees	(2,970)	(5,424)	–	(8,394)
Total investment return (loss), net of distributions and expenses	\$ 58,586	\$ (5,533)	\$ (110,555)	\$ (57,502)

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

6. Investments (continued)

	2019			
	Operating	Nonoperating	With Donor Restrictions	Total
Distribution of endowment earnings and other	\$ 3,606	\$ –	\$ 133	\$ 3,739
Net realized gains	53	89,301	4,296	93,650
Net unrealized (losses) gains	–	(53,224)	25,869	(27,355)
Total investment return	3,659	36,077	30,298	70,034
Investment return, designated for current operations	55,475	(55,475)	–	–
Investment management fees	(2,546)	(4,586)	–	(7,132)
Total investment return (loss), net of distributions and expenses	\$ 56,588	\$ (23,984)	\$ 30,298	\$ 62,902

7. Endowment Funds

The College’s endowment consists of approximately 800 individual funds established for a variety of purposes. Its endowment includes both donor-restricted endowment funds and funds designated by the College to function as endowments. As required by U.S. GAAP, net assets associated with endowment funds, including funds designated by the College to function as endowments, are classified and reported based on the existence or absence of donor-imposed restrictions.

ASC 958-205-45-28, *Not-for-Profit Entities – Presentation of Financial Statements – Other Presentation Matters – Classification of Donor-Restricted Endowment Funds Subject to UPMIFA*, provides guidance on the net asset classification of donor-restricted endowment funds for a not-for-profit organization that is subject to an enacted version of the Uniform Prudent Management of Institutional Funds Act of 2006 (UPMIFA) and improves disclosures about an organization’s endowment funds (both donor-restricted and College-designated endowment funds).

Interpretation of relevant law – The College has established policy consistent with UPMIFA as adopted by the state of Texas. The College seeks to preserve the fair value of the original gift as of the gift date of the donor-restricted endowment funds absent explicit donor stipulations to the contrary. Accordingly, the College classified as net assets with donor restrictions (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment, and (c) accumulations to the permanent endowment made in accordance with the direction of the applicable donor agreement at the time the accumulation is

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

7. Endowment Funds (continued)

added to the fund. The remaining portion of the donor-restricted endowment fund that is not classified as permanent endowment is available for appropriation for expenditure by the College in a manner consistent with the standard of prudence prescribed by UPMIFA.

In accordance with UPMIFA, the College considers the following factors in making a determination to appropriate or accumulate donor-restricted endowment funds:

- (1) The duration and preservation of the fund
- (2) The purposes of the College and the donor-restricted endowment fund
- (3) General economic conditions
- (4) The possible effect of inflation and deflation
- (5) The expected total return from income and the appreciation of investments
- (6) Other resources of the College
- (7) The investment policies of the College

The College's endowment consists of the following net asset types at June 30 (in thousands):

	Without Donor Restrictions	With Donor Restrictions	Total
2020			
Donor-restricted endowment funds	\$ —	\$ 645,764	\$ 645,764
Board-designated endowment funds	543,126	12,165	555,291
Total endowments at June 30, 2020	\$ 543,126	\$ 657,929	\$ 1,201,055

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

7. Endowment Funds (continued)

	Without Donor Restrictions	With Donor Restrictions	Total
2019			
Donor-restricted endowment funds	\$ –	\$ 752,223	\$ 752,223
Board-designated endowment funds	546,346	12,248	558,594
Total endowments at June 30, 2019	\$ 546,346	\$ 764,471	\$ 1,310,817

Funds with deficiencies – From time to time, the fair value of the assets associated with the individual donor-restricted endowment funds may fall below the level that the donor or UPMIFA requires the College to retain as a fund of perpetual duration. As of June 30, 2020, the College had deficiencies of this nature in 70 donor-restricted endowment funds, which together have an original gift value of \$41.0 million, a current fair value of \$38.8 million, and a deficiency of \$2.2 million. As of June 30, 2019, the College had deficiencies of this nature in 16 donor-restricted endowment funds, which together have an original gift value of \$10.8 million, a current fair value of \$10.7 million, and a deficiency of \$0.1 million. These deficiencies result from unfavorable market fluctuations and continued appropriation of certain programs that was deemed prudent by the Board of Trustees. The College maintains policies that permit spending from underwater endowment funds depending on the degree to which the fund is underwater, unless otherwise precluded by donor intent or relevant laws and regulations.

Return objectives and risk parameters – The College recognizes that the goals of endowment management are preserving the purchasing power of the assets and providing stable support for current programs. The primary focus of the College’s endowment investment policy is structuring both the endowment’s investment portfolio and its annual spending in order to balance the needs of current and future generations of scholars, scientists, patients, and teachers. Current annual spending from the endowment plus inflation combines to create a minimum target total return for the portfolio. The College expects its endowment funds, over time, to provide an average rate of return at least equal to the spending policy requirements plus the rate of inflation. Actual rates of return in any given year may vary from this amount.

Strategies employed for achieving objectives – The College employs strategies of investing in equity assets and some illiquid assets, broadly diversifying, and investing in assets that are out of favor. The College believes that these strategies will help achieve the total return target over the long term.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

7. Endowment Funds (continued)

Spending policy and how the investment objectives relate to spending policy – The College’s board-approved endowment earnings distribution policy, as permitted by UPMIFA, is based on a 5% distribution applied to a trailing 28-quarter average market value of the endowment assets for both fiscal years. In establishing this spending policy, the College considered the long-term expected return on its endowment assets and expects the current spending policy to preserve the real purchasing power of the endowment assets, while helping to maintain intergenerational value of the assets, as well as to provide additional real growth through new gifts and pledges and investment return.

The following endowment-related activities occurred during the years ended June 30 (in thousands):

	Without Donor Restrictions	With Donor Restrictions	Total
Endowment net assets at June 30, 2019	\$ 546,346	\$ 764,471	\$ 1,310,817
Investment income, net of expense	9,625	734	10,359
Gifts and pledges	7	5,604	5,611
Realized and unrealized gains (losses), net	43,880	(112,820)	(68,940)
Appropriation of endowment assets for expenditure	(56,732)	–	(56,732)
Other changes:			
Transfer from board-designated endowments within net assets without donor restrictions	–	(60)	(60)
Endowment net assets at June 30, 2020	<u>\$ 543,126</u>	<u>\$ 657,929</u>	<u>\$ 1,201,055</u>

	Without Donor Restrictions	With Donor Restrictions	Total
Endowment net assets at June 30, 2018	\$ 556,338	\$ 715,937	\$ 1,272,275
Investment income, net of expense	17,781	809	18,590
Gifts and pledges	7	18,316	18,323
Realized and unrealized gains, net	19,191	29,000	48,191
Appropriation of endowment assets for expenditure	(55,475)	–	(55,475)
Other changes:			
Transfer from board-designated endowments within net assets without donor restrictions	–	(55)	(55)
Reclassifications	8,504	464	8,968
Endowment net assets at June 30, 2019	<u>\$ 546,346</u>	<u>\$ 764,471</u>	<u>\$ 1,310,817</u>

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

8. Financial Assets and Liquidity Resources

The table below represents financial assets and liquidity resources available for general expenditures within one year. The College defines general expenditures as the normal expenditures related to operations, excluding capital expenditures (in thousands).

	June 30	
	2020	2019
Financial assets:		
Cash and cash equivalents	\$ 29,241	\$ 44,869
Accounts receivable	235,364	217,806
Pledges receivable	43,826	63,838
Notes receivable	17,866	15,265
Investments, including securities loaned of \$17,089 and \$34,044 for 2020 and 2019, respectively	1,224,606	1,340,869
Security lending collateral	17,701	34,984
Total financial assets	1,568,604	1,717,631
Liquidity resource:		
Unused bank line of credit	205,000	64,000
Less those unavailable for general expenditures within one year due to:		
Contractual or donor-imposed restrictions	(657,929)	(764,471)
Investments with liquidity restrictions	(3,689)	(11,126)
Investments held in trust	(9,482)	(8,074)
Pledges receivable	(19,969)	(27,761)
Notes receivable	(17,866)	(15,265)
Assets held on behalf of others	(42,106)	(44,694)
Security lending collateral	(17,701)	(34,984)
Financial assets not available for use within one year	(768,742)	(906,375)
Financial assets and liquidity resources available for general expenditures within one year	\$ 1,004,862	\$ 875,256

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

8. Financial Assets and Liquidity Resources (continued)

The College's endowment funds consist of donor-restricted endowments and funds designated by the board as endowment. Income from endowments is restricted for specific purposes. The College has a spending policy and \$57.9 million of appropriation from the endowments will be available in the next 12 months (see Note 7). As part of a liquidity management plan, the College has a policy to structure its financial assets to be available as its general expenditures, liabilities, and other obligations come due. Cash in excess of daily requirements is invested in short-term investments. In the event of an unanticipated liquidity need, the College has a 4-year \$150.0 million line of credit available for working capital purposes, and a supplemental 364-day \$100.0 million line of credit related to the COVID-19 pandemic (see Note 10).

9. Property and Equipment

Property and equipment consist of the following at June 30 (in thousands):

	Useful Life (Years)	2020	2019
Land	–	\$ 5,269	\$ 5,269
Buildings	17–50	706,426	689,932
Land improvements	15–20	16,483	16,483
Leasehold improvements	5–15	96,587	98,402
Furniture and equipment	5–10	337,308	317,556
Computer software	3–5	109,108	89,952
		1,271,181	1,217,594
Less accumulated depreciation		(914,675)	(869,153)
		356,506	348,441
Construction-in-progress		46,056	55,391
Leased right-of-use assets – financing		1,430	–
International operations, principally buildings, net	5–40	–	9,429
		\$ 403,992	\$ 413,261

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

9. Property and Equipment (continued)

In accordance with ASC 360, *Property, Plant, and Equipment*, when events or changes in circumstances indicate the carrying amount of property and equipment, and intangible or other long-lived assets, related to specifically acquired assets may not be recoverable, an evaluation of the recoverability of currently recorded costs is performed. When an evaluation is performed, the estimated value of undiscounted future net cash flows associated with the asset is compared to the asset's carrying value to determine whether a write-down to fair value is required. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. No impairments were recognized for the years ended June 30, 2020 or 2019.

10. Bonds and Notes Payable

A summary of bonds and notes payable at June 30 is as follows (in thousands):

	2020		2019
2012A Bond Series			
In September 2012, the Harris County Cultural Education Facilities Finance Corp. issued for the College \$202.88 million of tax-exempt fixed rate bonds. Interest rates range from 3.00% to 5.00%, payable semiannually. Principal installments are due annually through November 15, 2046. The bonds are callable beginning in November 2022.	\$	184,950	\$ 188,055
2012 Bond Series			
In September 2012, the College issued \$109.1 million of taxable fixed rate bonds. The interest rate is 5.26%, payable semiannually. Mandatory annual redemption before maturity is required between November 15, 2038 and 2045, with final maturity on November 15, 2046.		109,121	109,121
2016 Bond Series			
In May 2016, the Harris County Cultural Education Facilities Finance Corp. issued for the College \$142.66 million of tax-exempt fixed rate bonds with multiple maturities. The interest rates range from 3.00% to 5.00%, payable semiannually. Beginning in November 2018, principal installments are due annually with final maturity at November 15, 2032. A majority of the outstanding bonds are callable beginning in May 2026.		129,040	136,030

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

10. Bonds and Notes Payable (continued)

	2020	2019
2019A Bond Series		
In May 2019, the College retired \$75 million of tax-exempt floating rate notes with the Harris County Cultural Education Facilities Finance Corp. The Harris County Cultural Education Facilities Finance Corp. simultaneously issued \$75 million of tax-exempt floating rate notes. The interest rate resets monthly at a spread of 0.65% over the one-month London Interbank Offered Rate (LIBOR). The interest rate at June 30, 2020, was 0.77%. These bonds mature on November 15, 2046, but have an initial mandatory repurchase in July 2024.	\$ 75,000	\$ 75,000
2019B Bond Series		
In May 2019, the College retired a \$75 million direct placement loan with Barclays Bank. The Harris County Cultural Education Facilities Finance Corp simultaneously issued \$75 million of tax-exempt floating rate notes. The interest rate resets monthly at a spread of 0.65% over the one-month LIBOR. The interest rate at June 30, 2020 was 0.77%. This bond matures on November 15, 2046, but has an initial mandatory repurchase in July 2022.	75,000	75,000
Total outstanding	573,111	583,206
Less deferred issuance costs	(4,123)	(4,325)
Plus original issue premium – 2012A Bond Series	7,779	8,268
Plus original issue premium – 2016 Bond Series	9,928	12,100
	\$ 586,695	\$ 599,249

The aggregate annual scheduled maturities of long-term debt as of June 30, 2020, for the next five fiscal years and thereafter are as follows (in thousands):

2021	\$ 10,615
2022	11,160
2023	11,730
2024	12,330
2025	12,960
Thereafter	514,316
	\$ 573,111

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

10. Bonds and Notes Payable (continued)

In addition, the College must purchase a portion of its debt within these fiscal years unless remarketed, as described above.

Advance refunding tax-exempt debt is subject to arbitrage rules under Code Section 103(c) and related regulations that, in general, prohibit the yield realized from the investment of the proceeds of the new debt from exceeding the yield on the debt itself. Compliance with those rules is necessary for the interest on the debt to be exempt from federal income tax, and the College believes that it is in compliance with those rules.

As of June 30, 2020, all bonds outstanding have been issued under terms of the Amended and Restated Master Trust Indenture, dated September 6, 2012, between the Master Trustee and the College, as amended by one supplemental master trust indenture. The Master Trustee has a secured interest in all gross receipts and substantially all College land, including all improvements, appurtenances, personal property, and proceeds now or hereafter placed, acquired, or arising from the land.

Bond Compliance

As of June 30, 2020, the College is in compliance with financial covenants per the Amended and Restated Master Trust Indenture dated September 6, 2012.

Revolving Credit Line

During fiscal year 2020, the College refinanced the revolving line of credit to increase its size by an additional \$60.0 million to \$150.0 million, and extended its maturity to June 30, 2024. The College had drawn \$45.0 million and \$26.0 million for working capital purposes at June 30, 2020 and 2019, respectively. Effective April 9, 2020, the College secured a supplemental 364-day \$100.0 million line of credit that provides additional liquidity and flexibility during the COVID-19 pandemic. At June 30, 2020, there are no amounts outstanding on this supplemental line of credit.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

11. Derivative and Other Financial Instruments

The College has derivative financial instruments, as allowed by its Debt and Swap Policies' Guidelines, both of which specifically preclude their use for speculation. During fiscal year 2020, the College novated the front 12 years of its swap transaction with Barclays Bank PLC to PNC Bank, N.A while the remaining years remained with Barclays as a forward starting swap with zero notional amount. As a result of the novation, the fixed rate paid by the College increased from 4.274% to 4.542% and all the posted collateral with Barclays Bank PLC was released. The PNC Bank, N.A. swap transaction does not have any collateral posting requirements. Also during 2020, the College executed an amendment to its outstanding swap transaction with Bank of America, N.A. increasing the collateral posting threshold from \$20.0 million to \$30.0 million. The fixed rate paid by the College increased from 4.443% to 4.554%. The notional amount reduction for the Bank of America, N.A. swap in fiscal year 2021 will be \$0.5 million. The notional increase will be \$0.5 million for the PNC Bank swap.

The College has not elected hedge treatment of these swap agreements; as such, the change in the fair value of interest rate swaps is recorded in nonoperating unrealized loss on interest rate swaps on the consolidated statements of activities and as an adjustment to reconcile operating activity on the consolidated statements of cash flows. These long-dated swaps have a predetermined annual notional amortization that occurs in November each year.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

11. Derivative and Other Financial Instruments (continued)

The following table summarizes the fair value from the College's perspective at June 30, and the income (loss) recorded related to the interest rate swap agreements as of and for the years ended June 30 (dollars in thousands):

Counterparty	Barclays Bank PLC	PNC Bank	Bank of America/ Merrill Lynch	Total
Description	Fixed rate	Fixed rate	Fixed rate	
Effective date	February 2032	February 2020	January 2012	
Termination date	November 2045	February 2032	November 2047	
Notional amount	\$ —	\$ 101,860	\$ 41,940	\$ 143,800
Fixed rate	4.274%	4.542%	4.554%	
Fair value:				
2020	\$ (32,368)	\$ (46,314)	\$ (27,327)	\$ (106,009)
2019	(53,463)	—	(19,310)	(72,773)
Collateral posted:				
2020	\$ —	\$ —	\$ 980	\$ 980
2019	5,740	—	850	6,590
Gain (loss) recorded:				
2020	\$ 21,095	\$ (46,314)	\$ (8,017)	\$ (33,236)
2019	(16,575)	—	(4,369)	(20,944)

12. Fair Value of Assets and Liabilities

The estimated fair values of all significant financial instrument amounts have been determined by the College using available market information and appropriate valuation methodologies. The estimates are not necessarily indicative of the amounts the College could realize in a current market exchange.

The carrying amounts of cash and cash equivalents, accounts receivable, patient accounts receivable, accounts payable, and short-term line of credit approximate fair value because of their short maturity.

The College's bonds payable are reported at carrying value (par) net of unamortized premiums/discounts. The fair value of the bonds payable was \$637.7 million and \$636.3 million as of June 30, 2020 and 2019, respectively, based on a combination of Level 1 and Level 2 inputs.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

12. Fair Value of Assets and Liabilities (continued)

The College records investments, investments loaned under its security lending agreements, the related payable under security lending agreements, and its bond interest rate swap instruments at fair value in accordance with ASC 820.

ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The statement establishes consistency and comparability by providing a fair value hierarchy that prioritizes the inputs to valuation techniques into three broad levels, which are described below.

Level 1 – Inputs are quoted market prices in active markets for identical assets or liabilities (these are observable market inputs) that the College has the ability to access at the reporting date.

Level 2 – Inputs are other than quoted prices included within Level 1 that are either directly or indirectly observable for the asset or liability, including quoted market prices for similar assets in active markets, quoted prices for identical or similar assets in markets in which there are few transactions, inputs other than quoted prices that are observable for the asset, and inputs that are derived from observable market data by correlation or other means.

Level 3 – Inputs are generally unobservable market inputs that typically reflect the entity's estimate of assumptions that market participants would use in pricing the asset or liability (used when little or no market data is available).

ASC 820 requires the use of observable market inputs (quoted market prices) when measuring fair value whenever possible and requires Level 1 quoted prices to be used to measure fair value whenever possible.

ASC 820 provides guidance for estimating the fair value of investments in certain entities that calculate net asset value per share (or its equivalent). As such, the College utilizes net asset value as a practical expedient of fair value and other available information to determine fair value for investments meeting the prescribed requirements.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

12. Fair Value of Assets and Liabilities (continued)

Level 1 investments are able to be liquidated as of the reporting date at published market values. Level 2 and 3 investments may contain restrictions on the ability to liquidate assets at the reporting date. Investments that can be liquidated within 90 days of the reporting date at net asset value or its equivalent are classified as Level 2 investments. Investments classified as Level 3 have significant liquidity restrictions that would prevent redemption within 90 days of the reporting date, if at all. The following tables do not include private equity investments of \$365.5 million and \$393.1 million which are measured at fair value using net asset value as a practical expedient.

Financial assets and liabilities included in the College's consolidated financial statements and measured at fair value on a recurring basis as of June 30 are classified based on the applicable valuation technique level in the following tables (in thousands):

	Total 2020	Quoted Prices in Active Markets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Assets:				
Cash and cash equivalents	\$ 50,571	\$ 50,571	\$ —	\$ —
U.S. equities	423,198	283,415	139,783	—
International equities	287,343	199,087	88,256	—
Fixed income	97,083	24,379	72,704	—
Security lending collateral	17,701	—	17,701	—
	<u>\$ 875,896</u>	<u>\$ 557,452</u>	<u>\$ 318,444</u>	<u>\$ —</u>
Liabilities:				
Interest rate swap liability	\$ 106,009	\$ —	\$ 106,009	\$ —
Payable under security lending agreements	17,701	—	17,701	—
Assets held on behalf of others	31,145	31,145	—	—
	<u>\$ 154,855</u>	<u>\$ 31,145</u>	<u>\$ 123,710</u>	<u>\$ —</u>

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

12. Fair Value of Assets and Liabilities (continued)

	Total 2019	Quoted Prices in Active Markets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Assets:				
Cash and cash equivalents	\$ 98,722	\$ 98,722	\$ –	\$ –
U.S. equities	441,403	289,994	151,171	238
International equities	325,483	215,343	99,014	11,126
Fixed income	108,517	–	108,517	–
Security lending collateral	34,044	–	34,044	–
	<u>\$ 1,008,169</u>	<u>\$ 604,059</u>	<u>\$ 392,746</u>	<u>\$ 11,364</u>
Liabilities:				
Interest rate swap liability	\$ 72,773	\$ –	\$ 72,773	\$ –
Payable under security lending agreements	34,984	–	34,984	–
Assets held on behalf of others	34,010	34,010	–	–
	<u>\$ 141,767</u>	<u>\$ 34,010</u>	<u>\$ 107,757</u>	<u>\$ –</u>

Cash and cash equivalents and U.S. and international equities included in Level 1 are measured using quoted market prices in active markets for the identical equities. U.S. and international equities and fixed-income investments, included in Level 2, are measured using quoted market prices for similar assets and using the net asset value per share. Non-marketable international equities included in Level 3 are biotechnology startup companies generally based on technology derived from the College's clinical and research activities; as such, observable market prices are not available. These are valued using a combination of last outside transaction price and internal information on the progress of the technology.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

12. Fair Value of Assets and Liabilities (continued)

Private equity investments consist of leveraged buy-outs, venture capital, distressed debt, and real assets and real estate investments. Capital is allocated to domestic and international markets in various investment vehicles, primarily limited partnerships, but also includes private real estate investment trusts. Most of the underlying assets in the private equity partnerships are not immediately liquid. All private equity investments are held as long-term investments. Leveraged buy-outs, venture capital, and distressed debt investments are structured as closed-end, commitment-based investment funds where the investor commits a specified amount of capital upon inception of the fund, which is then drawn down over a specified period of the fund's life. These funds generally cannot be withdrawn or redeemed prior to the specified termination date and will only receive distributions upon a disposition of the underlying assets in the portfolio. As a limited partner, the College will not generally have any influence over the amount or timing of capital contributions and distributions. At June 30, 2020, the remaining specified term of the leveraged buy-outs, venture capital, and distressed debt partnerships ranged from 1 to 12 years. However, a partnership's life may be (and normally is) extended beyond the original specified term by approval of the limited partners. Some of the College's real estate investments are different from the other private equity partnerships, as they are structured as open-ended, commingled investment vehicles. The underlying investments consist of large, diversified portfolios of existing real properties, primarily income-producing assets, such as office buildings, apartments, retail, and industrial properties, located across the United States. Subject to certain restrictions, redemptions of all or part of the College's investments in private equity real estate may be requested each quarter, and such redemptions will be made at the net asset value for the fund. Private equity investment valuation is determined by the private equity general partner using proprietary information that is unobservable to a market participant.

Interest rate swap liability (see Note 11) valuation is determined using market valuation techniques, including discounted cash flow analysis on the expected cash flow of each agreement. This analysis reflects the contractual terms of the agreement, including the period to maturity, and uses observable market-based inputs, including forward interest rate curves. These observable (Level 2) inputs are available to a market participant.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

12. Fair Value of Assets and Liabilities (continued)

The following is a reconciliation of activity for assets measured at fair value based on using significant unobservable inputs (Level 3) (in thousands):

	U.S. Equities	International Equities	Total
Balance at June 30, 2019	\$ 238	\$ 11,126	\$ 11,364
Realized and unrealized losses included in earnings, net	(238)	(11,126)	(11,364)
Purchases	-	-	-
Sales	-	-	-
Balance at June 30, 2020	\$ -	\$ -	\$ -

Change in unrealized losses included in other income related to assets held as of June 30, 2020, net	\$ (11,364)
--	-------------

	U.S. Equities	International Equities	Total
Balance at June 30, 2018	\$ 249	\$ 11,126	\$ 11,375
Realized and unrealized losses included in earnings, net	(11)	-	(11)
Purchases	-	-	-
Sales	-	-	-
Balance at June 30, 2019	\$ 238	\$ 11,126	\$ 11,364

Change in unrealized losses included in other income related to assets held as of June 30, 2019, net	\$ (11)
--	---------

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

13. Functional Expenses

The College's expenses relate principally to providing education, research, and clinical services. The functional expenses for these services are recorded directly or are allocated. Operation and maintenance of plant expense, depreciation expense, and interest expense are allocated to the various functional areas of the College based on the square footage of space occupied by each program and supporting service.

For the years ended June 30, expenses related to providing these services are as follows (in thousands):

	2020						
	Program Activities				Supporting Activities		
	Instruction	Research	Medical Services	Affiliated Hospital Programs	Management and General	Fundraising	Total Expenses
Direct							
Salaries, wages, and benefits	\$ 131,122	\$ 353,802	\$ 275,250	\$ 795,172	\$ 30,104	\$ 4,448	\$ 1,589,898
Services, supplies, and others	19,603	191,374	83,041	39,761	35,579	3,293	372,651
Allocated							
Operations and maintenance of plant	7,235	40,398	1,364	-	-	-	48,997
Depreciation and interest	9,165	64,942	9,447	63	-	-	83,617
Allocated expenses by functional area	<u>\$ 167,125</u>	<u>\$ 650,516</u>	<u>\$ 369,102</u>	<u>\$ 834,996</u>	<u>\$ 65,683</u>	<u>\$ 7,741</u>	<u>\$ 2,095,163</u>
	2019						
	Program Activities				Supporting Activities		
	Instruction	Research	Medical Services	Affiliated Hospital Programs	Management and General	Fundraising	Total Expenses
Direct							
Salaries, wages, and benefits	\$ 125,841	\$ 340,495	\$ 268,236	\$ 776,947	\$ 36,072	\$ 3,028	\$ 1,550,619
Services, supplies, and others	15,359	173,783	135,871	43,430	28,513	2,235	399,191
Allocated							
Operations and maintenance of plant	7,225	39,854	1,360	-	-	-	48,439
Depreciation and interest	9,011	63,355	11,903	67	-	-	84,336
Allocated expenses by functional area	<u>\$ 157,436</u>	<u>\$ 617,487</u>	<u>\$ 417,370</u>	<u>\$ 820,444</u>	<u>\$ 64,585</u>	<u>\$ 5,263</u>	<u>\$ 2,082,585</u>

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

14. Employee Benefits

Retirement Plan

Substantially all faculty and staff participate in the College's defined contribution retirement plan (the Plan). The Plan is a core benefit, and contributions are made by the College based on a formula using the employee's base annual salary. The College's contributions to the Plan in the years ended June 30, 2020 and 2019, were \$67.4 million and \$72.5 million, respectively. The assets of the Plan are administered by third parties.

15. Leases

The components of lease cost for the fiscal year ended June 30, 2020, were as follows (in thousands):

	<u>2020</u>
Financial lease expense:	
Amortization of right-of-use assets	\$ 528
Interest on lease liabilities	30
Operating lease expense	<u>15,040</u>
Total lease cost	<u>\$ 15,598</u>
Other information:	
Cash paid for amounts included in the measurement of lease liabilities:	
Operating cash flows from finance leases	\$ 30
Operating cash flows from operating leases	14,486
Financing cash flows from finance leases	464
Right-of-use assets obtained in exchange for new operating lease liabilities	1,090
Weighted average remaining lease term – finance leases (in years)	3.75
Weighted average remaining lease term – operating leases (in years)	12.35
Weighted discount rate – finance leases	1.76%
Weighted discount rate – operating leases	1.93%

The annual payments based on maturities is reported under *Commitments and Contingencies* (see Note 16).

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

16. Commitments and Contingencies

Leases

Annual payments based on maturities of the College's leases as of June 30, 2020 are as follows (in thousands):

	Operating Leases	Finance Leases
2021	\$ 11,925	\$ 464
2022	11,112	464
2023	11,157	464
2024	10,962	26
2025	10,833	—
Thereafter	63,368	—
Total undiscounted lease payments	119,357	1,418
Less: present value adjustment	(13,379)	(42)
Total discounted lease payments	<u>\$ 105,978</u>	<u>\$ 1,376</u>

Private Investments

The College has committed to invest in certain private investments over a period of time. The remaining private investment commitment as of June 30, 2020 and 2019, is \$303.0 million and \$267.5 million, respectively. Based on historical patterns, the College expects those amounts will be called into the partnerships for investment over the next three to five years and will be funded by assets of the endowment.

Self-Insurance Program for Professional Liability

Medical malpractice and other actions alleging wrongful conduct and seeking punitive damages are sometimes filed against physicians and the College's affiliated institutions. Since 1977, the College has maintained a medical malpractice self-insurance program (the Program) that until July 1, 2003, had been supplemented by reinsurance or excess insurance agreements with private insurance companies. Due to sharply increased costs, the College's favorable loss experience, and the positive effects of tort reform legislation, the College, effective July 1, 2003, elected not to

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

16. Commitments and Contingencies (continued)

purchase excess insurance coverage. To date, there has not been a settlement or jury verdict on a case that exceeded the self-insurance retention level that would have been required by the insurance market had the College decided to purchase coverage. The College continued to monitor the insurance market, and during fiscal year 2011, the College started purchasing reinsurance above a \$15 million self-insured retention. For the years ended June 30, 2020 and 2019, the College has purchased \$50 million in reinsurance above the \$15 million per occurrence and \$25 million aggregate self-insurance retention.

The Program's dedicated account is funded on a quasi-occurrence basis, meaning it is designed to cover the health care provider for an incident that happened while he or she was a participant no matter when the claim or lawsuit was filed, but if the incident upon which the claim or lawsuit is based was not reported to the College's Risk Management office the matter would be asserted against the coverage in the fiscal year in which reporting occurred. Settlements, judgments, and costs of defense are paid from a pool of a self-insured retention, depending on the year the claim occurred or was filed; several layers of excess coverage are available to respond to them. Funding for the Program has been actuarially determined to the level of \$35 million per occurrence and \$70 million aggregate for payment of medical malpractice losses and related expenses. For the period from July 1, 2003 through September 1, 2010, all risk of loss is borne by the College.

The College has been named as a defendant in various claims for damages resulting from alleged medical malpractice. The malpractice reserve, which includes reserves for incurred but not reported claims, is \$38.8 million and \$37.8 million as of June 30, 2020 and 2019, respectively.

This liability was determined on a discounted basis without consideration of any insurance recoveries. The discount rate used in calculating the actuarial present value at both June 30, 2020 and 2019, was 5%.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

17. Transactions With Affiliates

Included among the College's Board of Trustees are members from the banking, insurance, and legal communities who provide assistance in the development of policies and programs for the College. Also, certain trustees, faculty, and staff of the College participate in the management of affiliated hospitals with which the College has contracts to provide services. During fiscal years 2020 and 2019, the College paid legal and related professional fees of approximately \$4.2 million and \$2.4 million to law firms with which several board members are affiliated. Also, the College has received, from time to time, significant contributions from various board members and corporations with which board members are affiliated. These transactions have been entered into in the normal course of business. The College also enters into transactions in the normal course of business with BSLMC and Baylor Genetics.

18. Financial Responsibility Standards

The Financial Responsibility Standards issued by the Department of Education's (Department) requires an institution be financially responsible to participate in any title IV, Higher Education Act program. In February 2020, the Department issued a revised financial responsibility rule that adopts new accounting standards and revises definitions and terminology to calculate the composite score ratios. The regulation is effective for financial statement filings that are submitted to the Department after July 1, 2020.

The notes supporting the Financial Responsibility Supplemental Schedule are presented below:

Note A

Net assets with donor restrictions, as reported on the consolidated balance sheets, are presented below:

Temporarily restricted net assets	\$ 348,539
Permanently restricted net assets	459,476
Total net assets with donor restrictions	<u>\$ 808,015</u>

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

18. Financial Responsibility Standards (continued)

Note B

Endowment with donor restrictions, as reported in Footnote 7: Endowment funds, are presented below:

Temporarily restricted endowment	\$ 221,556
Permanently restricted endowment	436,373
Total endowment with donor restrictions	<u>657,929</u>

Note C

All debt obtained for long-term purposes, as reported on the consolidated balance sheets, is limited to the total net property, plant, and equipment for the expendable net assets calculation. The details are presented below:

Footnote 10: Bonds and notes payable	
Total outstanding balance of bonds and notes payable	\$ 573,111
Less deferred issuance costs	(4,123)
Plus original issue premium – 2012A Bond Series	7,779
Plus original issue premium – 2016 Bond Series	9,928
Total bonds and notes payable	<u>586,695</u>

Footnote 16: Commitment and contingences	
Lease liability – operating	105,978
Lease liability – financing	1,376
Total lease liability	<u>107,354</u>
All debt obtained for long-term purposes	<u>\$ 694,049</u>

Balance Sheet: Net property, plant, and equipment

Property and equipment, net	\$ 403,992
Plus leased right-to-use assets – operating	105,370
Total net property, plant, and equipment	<u>\$ 509,362</u>

All debt obtained for long-term purposes reported for the expendable net assets calculation is limited to \$509.4 million.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

18. Financial Responsibility Standards (continued)

Note D

Unsecured related party receivables is a component of the Affiliate receivables, as reported on the consolidated balance sheets:

Unsecured related party receivables	\$ 36,571
Other affiliate receivables	<u>75,941</u>
Total affiliate receivables	<u>\$ 112,512</u>

Note E

For the purpose of calculating the total revenue without donor restrictions and gains without donor restrictions, the investment returns reported under both operating and non-operating activities on the consolidated statement of activities are aggregated:

Operating – investment income, net of expenses	\$ 58,586
Non-operating – investment (loss), net of distribution	<u>(5,533)</u>
Net investment income	<u>\$ 53,053</u>

\$5.5 million is subtracted from the total operating revenue due to the aggregation of investment income.

Note F

The College's postretirement benefit obligation at June 30, 2020 is \$7.5 million, and is recorded in Accounts payable and other liabilities of \$191.7 million.

Supplementary Information

Baylor College of Medicine

Financial Responsibility Supplemental Schedule (In Thousands)

Primary Reserve Ratio

Expendable net assets:

Note	Financial Statement/ Footnote Disclosure	Line Item Description	Amount
	Consolidated balance sheets	Net assets without donor restrictions	\$ 358,776
	Consolidated balance sheets	Net assets with donor restrictions	808,015
Note A	See Note 18	Net assets with donor restrictions: restricted in perpetuity	(459,476)
Note B	See Note 18	Annuities, term endowments and life income funds with donor restrictions	(221,556)
	Not applicable	Intangible assets	-
	Consolidated balance sheets	Net property, plant and equipment	(403,992)
	Consolidated balance sheets	Leased right-to-use assets – operating	(105,370)
Note F	See Note 18	Post-employment and defined benefit pension liabilities	7,471
Note C	See Note 18	All debt obtained for long term purposes, not to exceed total net property, plant, and equipment	509,362
Note D	See Note 18	Unsecured related party receivables	(36,571)
		Expendable net assets	<u>\$ 456,659</u>

Total expenses without donor restrictions and losses without donor restrictions:

Note	Financial Statement/ Footnote Disclosure	Line Item Description	Amount
	Consolidated statement of activities	Total operating expenses	\$ 2,095,163
	Consolidated statement of activities	Non-operating losses without donor restrictions: Unrealized loss on interest rate swaps	33,236
	Consolidated statement of activities	Non-operating losses without donor restrictions: Equity in loss of unconsolidated affiliates – non-operating	8,460
	Consolidated statement of activities	Non-operating losses without donor restrictions: Other non-operating activities	771
		Total expenses without donor restrictions and losses without donor restrictions	<u>\$ 2,137,630</u>

Baylor College of Medicine

Financial Responsibility Supplemental Schedule (continued)
(In Thousands)

Equity Ratio

Modified net assets:

Note	Financial Statement/ Footnote Disclosure	Line Item Description	Amount
	Consolidated balance sheets	Net assets without donor restrictions	\$ 358,776
	Consolidated balance sheets	Net assets with donor restrictions	808,015
	Not applicable	Intangible assets	–
Note D	See Note 18	Unsecured related party receivables	(36,571)
		Modified net assets	\$ 1,130,220

Modified assets:

Note	Financial Statement/ Footnote Disclosure	Line Item Description	Amount
	Consolidated statement of activities	Total assets	\$ 2,412,843
	Not applicable	Intangible assets	–
Note D	See Note 18	Unsecured related party receivables	(36,571)
		Modified assets	\$ 2,376,272

Baylor College of Medicine

Financial Responsibility Supplemental Schedule (continued)
(In Thousands)

Net Income Ratio

Change in net assets without donor restrictions:

Note	Financial Statement/ Footnote Disclosure	Line Item Description	Amount
	Consolidated statement of activities	Change in net assets without donor restrictions	\$ (76,075)
		Change in net assets without donor restrictions	<u>\$ (76,075)</u>

Total revenue without donor restrictions and gains without donor restrictions:

Note	Financial Statement/ Footnote Disclosure	Line Item Description	Amount
	Consolidated statement of activities	Total operating revenue	\$ 2,066,883
	Consolidated statement of activities	Non-operating – gifts and pledges	205
Note E	See Note 18	Non-operating – investment loss, net of distribution	<u>(5,533)</u>
		Total revenue without donor restrictions and gains without donor restrictions	<u>\$ 2,061,555</u>

Reports and Schedules Required by
the Uniform Guidance and the
State of Texas Single Audit Circular



Ernst & Young LLP
1401 McKinney Street
Suite 2400
Houston, TX 77010

Tel: +1 713 750 1500
Fax: +1 713 750 1501
ey.com

Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with *Government Auditing Standards*

Management and Board of Trustees
Baylor College of Medicine

We have audited, in accordance with auditing standards generally accepted in the United States and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the consolidated financial statements of Baylor College of Medicine, which comprise the consolidated balance sheet as of June 30, 2020, and the related consolidated statements of activities, and cash flows for the year then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated October 5, 2020.

Internal Control Over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered Baylor College of Medicine's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of Baylor College of Medicine's internal control. Accordingly, we do not express an opinion on the effectiveness of Baylor College of Medicine's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct misstatements on a timely basis. A *material weakness* is a deficiency, or combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

Compliance and Other Matters

As part of obtaining reasonable assurance about whether Baylor College of Medicine's consolidated financial statements are free of material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Ernst + Young LLP

October 5, 2020



Ernst & Young LLP
1401 McKinney Street
Suite 2400
Houston, TX 77010

Tel: +1 713 750 1500
Fax: +1 713 750 1501
ey.com

Report of Independent Auditors on Compliance for Each Major Federal and State Program and Report on Internal Control Over Compliance Required by the Uniform Guidance and *State of Texas Single Audit Circular*

Management and Board of Trustees
Baylor College of Medicine

Report on Compliance for Each Major Federal and State Program

We have audited Baylor College of Medicine's compliance with the types of compliance requirements described in the U.S. Office of Management and Budget (OMB) *Compliance Supplement* that could have a direct and material effect on Baylor College of Medicine's major federal program and the types of compliance requirements described in the *State of Texas Single Audit Circular* that could have a direct and material effect on each of Baylor College of Medicine's major state programs for the year ended June 30, 2020. Baylor College of Medicine's major federal and state programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

Management's Responsibility

Management is responsible for compliance with federal and state statutes, regulations and the terms and conditions of its federal and state awards applicable to its federal and state programs.

Auditor's Responsibility

Our responsibility is to express an opinion on compliance for each of Baylor College of Medicine's major federal and state programs based on our audit of the types of compliance requirements referred to above.

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) and the *State of Texas Single Audit Circular*. Those standards, the Uniform Guidance, and the *State of Texas Single Audit Circular* require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal or state program occurred. An audit includes examining, on a test basis, evidence about Baylor College of Medicine's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for each major federal and state program. However, our audit does not provide a legal determination of Baylor College of Medicine's compliance.

Opinion on Each Major Federal and State Program

In our opinion, Baylor College of Medicine complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal and state programs for the year ended June 30, 2020.

Report on Internal Control Over Compliance

Management of Baylor College of Medicine is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered Baylor College of Medicine's internal control over compliance with the types of requirements that could have a direct and material effect on each major federal and state program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal or state program and to test and report on internal control over compliance in accordance with the Uniform Guidance and the *State of Texas Single Audit Circular*, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of Baylor College of Medicine's internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal or state program on a timely basis. *A material weakness in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal or state program will not be prevented, or detected and corrected, on a timely basis. *A significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal or state program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.



The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance and the *State of Texas Single Audit Circular*. Accordingly, this report is not suitable for any other purpose.

Ernst + Young LLP

March 31, 2021

Baylor College of Medicine
Schedule of Expenditures of Federal Awards
Year Ended June 30, 2020

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF AGRICULTURE							
AGRICULTURAL RESEARCH-BASIC AND APPLIED RESEARCH	10.001		\$ 13,963,002	\$ -	\$ -	\$ 13,963,002	\$ 599,943
PASS-THROUGH AWARD FROM:							
<i>PRAIRIE VIEW A&M</i> 1890 INSTITUTION CAPACITY BUILDING GRANTS	10.216	2018-38821-27766	19,771	-	-	19,771	-
AGRICULTURE AND FOOD RESEARCH INITIATIVE (AFRI)	10.310		848,737	-	-	848,737	569,126
PASS-THROUGH AWARD FROM:							
<i>UNIVERSITY OF IDAHO</i> AGRICULTURE AND FOOD RESEARCH INITIATIVE (AFRI)	10.310	2017-67016-26301	15,965	-	-	15,965	-
		<i>Total CFDA 10.310</i>	<u>864,702</u>	<u>-</u>	<u>-</u>	<u>864,702</u>	<u>569,126</u>
TOTAL DEPARTMENT OF AGRICULTURE			14,847,475	-	-	14,847,475	1,169,069
DEPARTMENT OF DEFENSE							
PASS-THROUGH AWARD FROM:							
<i>UNIVERSITY OF PITTSBURGH MEDICAL CENTER</i> BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	NS08609	59,091	-	-	59,091	-
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		12,619,725	-	-	12,619,725	402,346
PASS-THROUGH AWARD FROM:							
<i>BOSTON CHILDREN'S HOSPITAL</i> MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0532	37,740	-	-	37,740	-
<i>THE TRUSTEES OF BOSTON UNIVERSITY</i> MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-13-2-0072	1,508	-	-	1,508	-
<i>THE TRUSTEES OF BOSTON UNIVERSITY</i> MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0685	6,744	-	-	6,744	-
<i>THE TRUSTEES OF COLUMBIA UNIVERSITY</i> MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0166	19,650	-	-	19,650	-
<i>DUKE UNIVERSITY</i> MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-14-1-0473	861	-	-	861	-
<i>GEORGE WASHINGTON UNIVERSITY</i> MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0672	132,930	-	-	132,930	-
<i>JOHNS HOPKINS UNIVERSITY</i> MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH19-1-0292	1,875	-	-	1,875	-
<i>NORTHERN CALIFORNIA INSTITUTE FOR RESEARCH AND EDUCATION</i> MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-1-0558	25,248	-	-	25,248	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF DEFENSE (continued)							
PASS-THROUGH AWARD FROM (continued):							
<i>RESEARCH TRIANGLE INTERNATIONAL</i>							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-2-0077	\$ 478,967	\$ -	\$ -	\$ 478,967	\$ 12,060
<i>RICE UNIVERSITY</i>							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	DARPA N6001-19-C-4020	383,159	-	-	383,159	-
<i>STATE UNIVERSITY OF NEW YORK</i>							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-2-0012	29,363	-	-	29,363	-
<i>TULANE UNIVERSITY</i>							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0026	108,570	-	-	108,570	-
<i>UNIVERSITY OF CALIFORNIA, BERKELEY</i>							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0586	18,150	-	-	18,150	-
<i>UNIVERSITY OF CALIFORNIA, SAN FRANCISCO</i>							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-14-2-0176	91,116	-	-	91,116	-
<i>UNIVERSITY OF CALIFORNIA, SAN FRANCISCO</i>							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-9-0001	211,741	-	-	211,741	-
<i>UNIVERSITY OF CALIFORNIA, SAN FRANCISCO</i>							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-2-0042	31,223	-	-	31,223	-
<i>UNIVERSITY OF CINCINNATI</i>							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-6-2-0020	33,577	-	-	33,577	-
<i>UNIVERSITY OF ILLINOIS AT CHICAGO</i>							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-1-0044	(490)	-	-	(490)	-
<i>UNIVERSITY OF PITTSBURGH</i>							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-D-0024	193,465	-	-	193,465	5,530
<i>UNIVERSITY OF SOUTHERN CALIFORNIA</i>							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-14-1-0462	792	-	-	792	-
<i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON</i>							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0537	33,773	-	-	33,773	-
<i>THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER</i>							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0410	9,544	-	-	9,544	-
<i>VIRGINIA COMMONWEALTH UNIVERSITY</i>							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-13-2-0095	(17,977)	-	-	(17,977)	-
<i>WASHINGTON UNIVERSITY</i>							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0084	122,733	-	-	122,733	-
<i>WILLIAM BEAUMONT HOSPITAL RESEARCH INSTITUTE</i>							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-1-0307	53,862	-	-	53,862	-
<i>Total CFDA 12.420</i>			14,627,849	-	-	14,627,849	419,936

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF DEFENSE (continued)							
PASS-THROUGH AWARD FROM: HENRY JACKSON FOUNDATION UNIFORMED SERVICES UNIVERSITY MEDICAL RESEARCH PROJECTS	12.750	HU001-17-2-0023	\$ 11,192	\$ -	\$ -	\$ 11,192	\$ -
RESEARCH AND TECHNOLOGY DEVELOPMENT PASS-THROUGH AWARD FROM: THE TRUSTEES OF COLUMBIA UNIVERSITY RESEARCH AND TECHNOLOGY DEVELOPMENT UNIVERSITY OF WISCONSIN	12.910		717,175	-	-	717,175	371,783
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	N66001-17-C-4002	225,303	-	-	225,303	-
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	N66001-17-2-4010	250,364	-	-	250,364	-
<i>Total CFDA 12.910</i>			<u>1,192,842</u>	<u>-</u>	<u>-</u>	<u>1,192,842</u>	<u>371,783</u>
TOTAL DEPARTMENT OF DEFENSE			15,890,974	-	-	15,890,974	791,719
DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT							
LEAD-BASED PAINT HAZARD CONTROL IN PRIVATELY-OWNED HOUSING	14.900	TXHHU0043-18	444,690	-	-	444,690	41,561
TOTAL DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT			444,690	-	-	444,690	41,561
DEPARTMENT OF JUSTICE							
NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION AND DEVELOPMENT PROJECT GRANTS	16.560		57,032	-	-	57,032	-
PASS-THROUGH AWARD FROM: OFFICE OF THE GOVERNOR CRIME VICTIM ASSISTANCE	16.575	3849301	-	-	263,690	263,690	-
TOTAL DEPARTMENT OF JUSTICE			57,032	-	263,690	320,722	-
NATIONAL AERONAUTICS AND SPACE ADMINISTRATION							
AERONAUTICS	43.002	NCC9-58	11,922	-	-	11,922	9,699
EXPLORATION PASS-THROUGH AWARD FROM: UNIVERSITY OF WASHINGTON	43.003		19,237,273	-	-	19,237,273	14,653,590
EXPLORATION	43.003	NNX16AE78G	21,515	-	-	21,515	-
<i>Total CFDA 43.003</i>			<u>19,258,788</u>	<u>-</u>	<u>-</u>	<u>19,258,788</u>	<u>14,653,590</u>

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
NATIONAL AERONAUTICS AND SPACE ADMINISTRATION (continued)							
PASS-THROUGH AWARD FROM:							
INDIANA UNIVERSITY							
SPACE OPERATIONS	43.007	NNX15AL13G	\$ (20)	\$ -	\$ -	\$ (20)	\$ -
CENTER FOR ADVANCEMENT OF SCIENCE IN SPACE							
SPACE OPERATIONS	43.007	GA-2014-136	13,255	-	-	13,255	1,429
	43.007	GA-2018-270	125,598	-	-	125,598	-
	<i>Total CFDA 43.007</i>		<u>138,833</u>	<u>-</u>	<u>-</u>	<u>138,833</u>	<u>1,429</u>
TOTAL NATIONAL AERONAUTICS AND SPACE ADMINISTRATION			19,409,543	-	-	19,409,543	14,664,718
NATIONAL SCIENCE FOUNDATION							
ENGINEERING							
	47.041		89,466	-	-	89,466	38,115
MATHEMATICAL AND PHYSICAL SCIENCES							
	47.049		240,289	-	-	240,289	44,696
PASS-THROUGH AWARD FROM:							
RICE UNIVERSITY							
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	PHY-1427654	497,675	-	-	497,675	-
NORTH CAROLINA STATE UNIVERSITY							
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	IIS-1622451	69,320	-	-	69,320	-
UNIVERSITY OF HOUSTON							
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	DBI-1707400	392,052	-	-	392,052	-
UNIVERSITY OF ILLINOIS							
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	PHY-1430124	(13,395)	-	-	(13,395)	-
	<i>Total CFDA 47.049</i>		<u>1,185,941</u>	<u>-</u>	<u>-</u>	<u>1,185,941</u>	<u>44,696</u>
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING							
	47.070		103,755	-	-	103,755	-
PASS-THROUGH AWARD FROM:							
RICE UNIVERSITY							
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	CNS-1801865	9,505	-	-	9,505	-
	<i>Total CFDA 47.070</i>		<u>113,260</u>	<u>-</u>	<u>-</u>	<u>113,260</u>	<u>-</u>
BIOLOGICAL SCIENCES							
	47.074		254,650	-	-	254,650	-
PASS-THROUGH AWARD FROM:							
UNIVERSITY OF HOUSTON							
BIOLOGICAL SCIENCES	47.074	NSF-1457800	87	-	-	87	-
UNIVERSITY OF MICHIGAN							
BIOLOGICAL SCIENCES	47.074	NSF 1935265	73,278	-	-	73,278	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
NATIONAL SCIENCE FOUNDATION (continued)							
PASS-THROUGH AWARD FROM (continued):							
ARIZONA STATE UNIVERSITY							
BIOLOGICAL SCIENCES	47.074	NSF-1557890	\$ 66,546	\$ -	\$ -	\$ 66,546	\$ -
RICE UNIVERSITY							
BIOLOGICAL SCIENCES	47.074	NSF-1550994	13,358	-	-	13,358	-
		<i>Total CFDA 47.074</i>	407,919	-	-	407,919	-
PASS-THROUGH AWARD FROM:							
RICE UNIVERSITY							
EDUCATION AND HUMAN RESOURCES	47.076	DGE-1250104	7,104	-	-	7,104	-
TOTAL NATIONAL SCIENCE FOUNDATION			1,803,690	-	-	1,803,690	82,811
DEPARTMENT OF EDUCATION							
FEDERAL WORK-STUDY PROGRAM	84.033		-	135,662	-	135,662	-
FEDERAL PERKINS LOAN PROGRAM – FEDERAL CAPITAL CONTRIBUTIONS	84.038		-	3,351,613	-	3,351,613	-
PASS-THROUGH AWARD FROM:							
HOUSTON INDEPENDENT SCHOOL DISTRICT							
MAGNET SCHOOLS ASSISTANCE	84.165	Rusk Academy	-	-	91,889	91,889	-
MAGNET SCHOOLS ASSISTANCE	84.165	Ryan Academy	-	-	115,505	115,505	-
		<i>Total CFDA 84.165</i>	-	-	207,394	207,394	-
FEDERAL DIRECT STUDENT LOANS	84.268		-	16,857,027	-	16,857,027	-
TOTAL DEPARTMENT OF EDUCATION			-	20,344,302	207,394	20,551,696	-
DEPARTMENT OF HEALTH AND HUMAN SERVICES							
BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES – PREVENTION AND SURVEILLANCE	93.073		1,471	-	-	1,471	-
PASS-THROUGH AWARD FROM:							
ARKANSAS CHILDREN'S HOSPITAL							
BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES – PREVENTION AND SURVEILLANCE	93.073	DD001285	12,748	-	-	12,748	-
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON							
BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES – PREVENTION AND SURVEILLANCE	93.073	DD004942	18,405	-	-	18,405	-
		<i>Total CFDA 93.073</i>	32,624	-	-	32,624	-
FAMILY SMOKING PREVENTION AND TOBACCO CONTROL ACT REGULATORY RESEARCH	93.077		414,578	-	-	414,578	175,848

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM:							
<i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON</i>							
BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH	93.080	U27 DD001155	\$ 21,969	\$ -	\$ -	\$ 21,969	\$ -
PREVENTION OF DISEASE, DISABILITY AND DEATH BY INFECTIOUS DISEASES	93.084		48,222	-	-	48,222	-
FOOD AND DRUG ADMINISTRATION-RESEARCH	93.103		1,453,733	-	-	1,453,733	770,173
PASS-THROUGH AWARD FROM:							
<i>NEW YORK MEDICAL COLLEGE</i>							
FOOD AND DRUG ADMINISTRATION-RESEARCH	93.103	FD004090	19,657	-	-	19,657	-
Total CFDA 93.103			1,473,390	-	-	1,473,390	770,173
PASS-THROUGH AWARD FROM:							
<i>CITY OF HOUSTON</i>							
COMPREHENSIVE COMMUNITY MENTAL HEALTH SERVICES FOR CHILDREN WITH SERIOUS EMOTIONAL DISORDER (SED)	93.104	SM082256	-	-	18,082	18,082	-
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110		-	-	692,303	692,303	-
PASS-THROUGH AWARD FROM:							
<i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON</i>							
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	MC24051-PROGRAM INCOME	-	-	904,420	904,420	-
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	H30MC24051	-	-	24,209	24,209	-
Total CFDA 93.110			-	-	1,620,932	1,620,932	-
ENVIRONMENTAL HEALTH	93.113		2,933,595	-	-	2,933,595	561,927
PASS-THROUGH AWARD FROM:							
<i>THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON</i>							
ENVIRONMENTAL HEALTH	93.113	ES016302	18,029	-	-	18,029	-
<i>COLORADO STATE UNIVERSITY</i>							
ENVIRONMENTAL HEALTH	93.113	ES029766	15,611	-	-	15,611	-
<i>OREGON STATE UNIVERSITY</i>							
ENVIRONMENTAL HEALTH	93.113	ES029460	22,460	-	-	22,460	-
<i>UNIVERSITY OF ILLINOIS AT CHICAGO</i>							
ENVIRONMENTAL HEALTH	93.113	ES028615	254,940	-	-	254,940	-
Total CFDA 93.113			3,244,635	-	-	3,244,635	561,927

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
ORAL DISEASES AND DISORDERS RESEARCH	93.121		\$ 721,772	\$ -	\$ -	\$ 721,772	\$ 36,789
PASS-THROUGH AWARD FROM:							
<i>THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER</i>							
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE024601	3,447	-	-	3,447	-
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE025181	374	-	-	374	-
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE025248	2,855	-	-	2,855	-
<i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON</i>							
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE024392	(365)	-	-	(365)	-
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE027794-02	4,322	-	-	4,322	-
<i>RICE UNIVERSITY</i>							
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE021798	110,979	-	-	110,979	-
<i>FRED HUTCHINSON CANCER RESEARCH</i>							
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE027850	50,690	-	-	50,690	-
		Total CFDA 93.121	894,074	-	-	894,074	36,789
EMERGENCY MEDICAL SERVICES FOR CHILDREN	93.127		-	-	1,485,959	1,485,959	-
PASS-THROUGH AWARD FROM:							
<i>COLUMBIA UNIVERSITY</i>							
EMERGENCY MEDICAL SERVICES FOR CHILDREN	93.127	MC00007	-	-	158,758	158,758	-
<i>UNIVERSITY OF BUFFALO</i>							
EMERGENCY MEDICAL SERVICES FOR CHILDREN	93.127	MC33154-01-00	-	-	82,708	82,708	-
<i>MEDICAL COLLEGE OF WISCONSIN</i>							
EMERGENCY MEDICAL SERVICES FOR CHILDREN	93.127	MC26201-01-00	-	-	25,996	25,996	-
		Total CFDA 93.127	-	-	1,753,421	1,753,421	-
PASS-THROUGH AWARD FROM:							
<i>EASTERN VIRGINIA MEDICAL</i>							
CENTERS FOR RESEARCH AND DEMONSTRATION FOR HEALTH PROMOTION AND DISEASE PREVENTION	93.135	S270151-27	2,035	-	-	2,035	-
<i>THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER</i>							
CENTERS FOR RESEARCH AND DEMONSTRATION FOR HEALTH PROMOTION AND DISEASE PREVENTION	93.135	HHSN261201200034i	7,046	-	-	7,046	-
		Total CFDA 93.135	9,081	-	-	9,081	-
PASS-THROUGH AWARD FROM:							
<i>HARRIS COUNTY</i>							
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	CE924976	12,798	-	-	12,798	-
		Total CFDA 93.136	12,798	-	-	12,798	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
NIEHS SUPERFUND HAZARDOUS SUBSTANCES - BASIC RESEARCH AND EDUCATION PASS-THROUGH AWARD FROM: TEXAS A&M UNIVERSITY	93.143		\$ 116,102	\$ -	\$ -	\$ 116,102	\$ -
NIEHS SUPERFUND HAZARDOUS SUBSTANCES - BASIC RESEARCH AND EDUCATION THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER	93.143	ES027704	235,782	-	-	235,782	-
NIEHS SUPERFUND HAZARDOUS SUBSTANCES - BASIC RESEARCH AND EDUCATION	93.143	CA016672	36,511	-	-	36,511	-
TOTAL CFDA 93.143			388,395	-	-	388,395	-
PASS-THROUGH AWARD FROM:							
HARRIS HEALTH SYSTEM HIV-RELATED TRAINING AND TECHNICAL ASSISTANCE UNIVERSITY OF WASHINGTON	93.145	U10HA29290	(284)	-	-	(284)	-
HIV-RELATED TRAINING AND TECHNICAL ASSISTANCE UNIVERSITY OF NEW MEXICO	93.145	HA06801-14-00	2,348	-	-	2,348	-
HIV-RELATED TRAINING AND TECHNICAL ASSISTANCE	93.145	HA33225	164,580	-	-	164,580	-
Total CFDA 93.145			166,644	-	-	166,644	-
CENTERS OF EXCELLENCE	93.157		648,171	-	-	648,171	-
PASS-THROUGH AWARD FROM:							
TEXAS TECH UNIVERSITY HEALTH PROGRAM FOR TOXIC SUBSTANCES AND DISEASE REGISTRY	93.161	TS000238-R6-0	2	-	-	2	-
HUMAN GENOME RESEARCH PASS-THROUGH AWARD FROM: KAISER PERMANENTE	93.172		22,658,417	-	-	22,658,417	1,219,183
HUMAN GENOME RESEARCH JOHNS HOPKINS UNIVERSITY	93.172	HG007292	17,461	-	-	17,461	-
HUMAN GENOME RESEARCH UNIVERSITY OF WASHINGTON	93.172	HG006542	1,260,927	-	-	1,260,927	-
HUMAN GENOME RESEARCH STANFORD UNIVERSITY	93.172	HG006493	(1,179)	-	-	(1,179)	-
HUMAN GENOME RESEARCH HARVARD MEDICAL SCHOOL	93.172	HG09649	1,184,993	-	-	1,184,993	-
HUMAN GENOME RESEARCH	93.172	HG007530-06	305,510	-	-	305,510	-
Total CFDA 93.172			25,426,129	-	-	25,426,129	1,219,183

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173		\$ 4,216,075	\$ -	\$ -	\$ 4,216,075	\$ 839,065
PASS-THROUGH AWARD FROM:							
<i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON</i>							
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC014589	30,386	-	-	30,386	-
<i>UNIVERSITY OF SOUTHERN CALIFORNIA</i>							
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC014450-07	2,975	-	-	2,975	-
<i>UNIVERSITY OF UTAH</i>							
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC014706	1,476	-	-	1,476	-
	Total CFDA 93.173		4,250,912	-	-	4,250,912	839,065
NATIONAL RESEARCH SERVICE AWARD IN PRIMARY CARE MEDICINE	93.186		240,771	-	-	240,771	-
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213		768,352	-	-	768,352	-
PASS-THROUGH AWARD FROM:							
<i>DUKE UNIVERSITY</i>							
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	AT009676	42,460	-	-	42,460	-
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	AT010961	27,739	-	-	27,739	-
<i>UNIVERSITY OF ALABAMA AT BIRMINGHAM</i>							
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	AT008621	7,175	-	-	7,175	-
<i>UNIVERSITY OF ARIZONA</i>							
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	AT008621	41,518	-	-	41,518	-
	Total CFDA 93.213		887,244	-	-	887,244	-
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226		2,094,332	-	-	2,094,332	54,923
PASS-THROUGH AWARD FROM:							
<i>ALBERT EINSTEIN COLLEGE OF MEDICINE</i>							
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS023608	(1,846)	-	-	(1,846)	-
<i>UNIVERSITY OF MICHIGAN</i>							
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS024385	5,016	-	-	5,016	-
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS024953	79,656	-	-	79,656	-
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS026622	39,706	-	-	39,706	-
<i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON</i>							
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS024459	6,405	-	-	6,405	-
<i>UNIVERSITY OF COLORADO</i>							
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS024597	15,473	-	-	15,473	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM:							
<i>UNIVERSITY OF HOUSTON</i>							
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS026790	\$ 3,582	\$ -	\$ -	\$ 3,582	\$ -
<i>KAISER PERMANENTE</i>							
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS024437	692	-	-	692	-
Total CFDA 93.226			2,243,016	-	-	2,243,016	54,923
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233		389,530	-	-	389,530	-
MENTAL HEALTH RESEARCH GRANTS	93.242		8,757,959	-	-	8,757,959	682,322
PASS-THROUGH AWARD FROM:							
<i>ALLEN BRAIN INSTITUTE</i>							
MENTAL HEALTH RESEARCH GRANTS	93.242	MH114830	844,770	-	-	844,770	9,963
<i>UNIVERSITY OF COLORADO DENVER</i>							
MENTAL HEALTH RESEARCH GRANTS	93.242	MH121362-01	5,776	-	-	5,776	-
<i>UNIVERSITY OF MICHIGAN</i>							
MENTAL HEALTH RESEARCH GRANTS	93.242	MH104311	10,750	-	-	10,750	-
<i>THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON</i>							
MENTAL HEALTH RESEARCH GRANTS	93.242	MH100930	124,877	-	-	124,877	-
<i>UNIVERSITY OF PITTSBURGH</i>							
MENTAL HEALTH RESEARCH GRANTS	93.242	MH113857	(60)	-	-	(60)	-
<i>UNIVERSITY OF SOUTH FLORIDA</i>							
MENTAL HEALTH RESEARCH GRANTS	93.242	MH107522	30,300	-	-	30,300	-
<i>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</i>							
MENTAL HEALTH RESEARCH GRANTS	93.242	MH111932	98,782	-	-	98,782	-
<i>UNIVERSITY OF TENNESSEE</i>							
MENTAL HEALTH RESEARCH GRANTS	93.242	MH112143	27,844	-	-	27,844	-
<i>UNIVERSITY OF NORTH CAROLINA</i>							
MENTAL HEALTH RESEARCH GRANTS	93.242	MH104102	56,284	-	-	56,284	-
MENTAL HEALTH RESEARCH GRANTS	93.242	MH118249	25,864	-	-	25,864	-
MENTAL HEALTH RESEARCH GRANTS	93.242	MH110925	592	-	-	592	-
Total CFDA 93.242			9,983,738	-	-	9,983,738	692,285
SUBSTANCE ABUSE & MENTAL HEALTH SERVICES – PROJECTS OF REGIONAL & NATIONAL SIGNIFICANCE	93.243		-	-	596,832	596,832	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
<i>SANTA MARIA HOSTEL</i>							
SUBSTANCE ABUSE & MENTAL HEALTH SERVICES PROJECTS OF REGIONAL & NATIONAL SIGNIFICANCE	93.243	TI026362	\$ -	\$ -	\$ 109,671	\$ 109,671	\$ -
<i>BEHAVIORAL HEALTH SOLUTIONS</i>							
SUBSTANCE ABUSE & MENTAL HEALTH SERVICES PROJECTS OF REGIONAL & NATIONAL SIGNIFICANCE	93.243	TI080684	-	-	87,555	87,555	-
<i>CENTER FOR RECOVERY AND WELLNESS RESOURCES</i>							
SUBSTANCE ABUSE & MENTAL HEALTH SERVICES PROJECTS OF REGIONAL & NATIONAL SIGNIFICANCE	93.243	TI026609	-	-	16,616	16,616	-
SUBSTANCE ABUSE & MENTAL HEALTH SERVICES PROJECTS OF REGIONAL & NATIONAL SIGNIFICANCE	93.243	TI080624	-	-	124,024	124,024	-
<i>THE UNIVERSITY OF TEXAS AT SAN ANTONIO</i>							
SUBSTANCE ABUSE & MENTAL HEALTH SERVICES PROJECTS OF REGIONAL & NATIONAL SIGNIFICANCE	93.243	TI026787	-	-	56,794	56,794	-
<i>CITY OF HOUSTON</i>							
SUBSTANCE ABUSE & MENTAL HEALTH SERVICES PROJECTS OF REGIONAL & NATIONAL SIGNIFICANCE	93.243	SP080300	-	-	43,069	43,069	-
<i>THE UNIVERSITY OF TEXAS AT RIO GRANDE VALLEY</i>							
SUBSTANCE ABUSE & MENTAL HEALTH SERVICES PROJECTS OF REGIONAL & NATIONAL SIGNIFICANCE	93.243	TI025979	-	-	5	5	-
Total CFDA 93.243			-	-	1,034,566	1,034,566	-
OCCUPATIONAL SAFETY AND HEALTH PROGRAM	93.262		451,717	-	-	451,717	173,037
PASS-THROUGH AWARD FROM:							
<i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON</i>							
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.262	OH008421-13	2,512	-	-	2,512	-
Total CFDA 93.262			454,229	-	-	454,229	173,037
ALCOHOL RESEARCH PROGRAMS	93.273		24,762	-	-	24,762	-
PASS-THROUGH AWARD FROM:							
<i>YALE UNIVERSITY</i>							
ALCOHOL RESEARCH PROGRAMS	93.273	AA020795	149,488	-	-	149,488	-
<i>THE UNIVERSITY OF TEXAS AT AUSTIN</i>							
ALCOHOL RESEARCH PROGRAMS	93.273	AA022924	106,775	-	-	106,775	-
<i>UNIVERSITY OF HOUSTON</i>							
ALCOHOL RESEARCH PROGRAMS	93.273	AA023739	70,086	-	-	70,086	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
<i>UNIVERSITY OF LOUISVILLE</i>							
ALCOHOL RESEARCH PROGRAMS	93.273	AA026225	\$ 37,490	\$ -	\$ -	\$ 37,490	\$ -
<i>SCRIPPS RESEARCH INSTITUTE</i>	93.273	AA021667	39,508	-	-	39,508	-
Total CFDA 93.273			428,109	-	-	428,109	-
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		417,174	-	-	417,174	307,505
PASS-THROUGH AWARD FROM:							
<i>THE METHODIST HOSPITAL RESEARCH INSTITUTE</i>							
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	DA030338	140,320	-	-	140,320	-
<i>SCRIPPS RESEARCH INSTITUTE</i>	93.279	DA043268	74,915	-	-	74,915	-
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	DA046170	118,735	-	-	118,735	-
<i>UNIVERSITY OF IOWA</i>	93.279	DA026437	10,773	-	-	10,773	-
<i>UNIVERSITY OF HOUSTON</i>	93.279	HD095520	127,667	-	-	127,667	-
Total CFDA 93.279			889,584	-	-	889,584	307,505
DISCOVERY & APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286		1,612,973	-	-	1,612,973	305,611
PASS-THROUGH AWARD FROM:							
<i>RICE UNIVERSITY</i>							
DISCOVERY & APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	LM007093	48,778	-	-	48,778	-
DISCOVERY & APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB023431	27,274	-	-	27,274	-
<i>TEXAS A&M UNIVERSITY</i>	93.286	EB025945	55,433	-	-	55,433	-
<i>WAYNE STATE UNIVERSITY</i>	93.286	E026453	331,391	-	-	331,391	-
Total CFDA 93.286			2,075,849	-	-	2,075,849	305,611

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307		\$ 430,340	\$ -	\$ -	\$ 430,340	\$ 56,953
PASS-THROUGH AWARD FROM:							
<i>UNIVERSITY OF PITTSBURGH</i>							
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD009118	(1,075)	-	-	(1,075)	-
<i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON</i>							
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD012942	14,599	-	-	14,599	-
<i>THE UNIVERSITY OF TEXAS AT AUSTIN</i>							
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD009675	38,930	-	-	38,930	-
		TOTAL CFDA 93.307	482,794	-	-	482,794	56,953
TRANS-NIH RESEARCH SUPPORT	93.310		10,412,027	-	-	10,412,027	1,639,137
PASS-THROUGH AWARD FROM:							
<i>THE UNIVERSITY OF TEXAS AT EL PASO</i>							
TRANS-NIH RESEARCH SUPPORT	93.310	GM118969	(16,164)	-	-	(16,164)	-
TRANS-NIH RESEARCH SUPPORT	93.310	GM118971	7,773	-	-	7,773	-
<i>MASSACHUSETTS GENERAL HOSPITAL</i>							
TRANS-NIH RESEARCH SUPPORT	93.310	OD023253	36,892	-	-	36,892	-
<i>RICE UNIVERSITY</i>							
TRANS-NIH RESEARCH SUPPORT	93.310	HL151545	167,392	-	-	167,392	-
<i>UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN</i>							
TRANS-NIH RESEARCH SUPPORT	93.310	OD023272	27,021	-	-	27,021	-
		Total CFDA 93.310	10,634,941	-	-	10,634,941	1,639,137
RARE DISORDERS: RESEARCH, SURVEILLANCE, HEALTH PROMOTION, AND EDUCATION	93.315		76,204	-	-	76,204	-
STRENGTHENING PUBLIC HEALTH THROUGH SURVEILLANCE, EPIDEMIOLOGIC RESEARCH, DISEASE DETECTION AND PREVENTION	93.326		286,887	-	-	286,887	-
HEALTH PROFESSIONS STUDENT LOANS, INCLUDING PRIMARY CARE LOANS/ LOANS FOR DISADVANTAGED STUDENTS	93.342		-	543,011	-	543,011	-
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350		8,668	-	-	8,668	8,668

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM:							
<i>DYSTONIA MEDICAL RESEARCH FOUNDATION</i>							
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR001456	\$ 91	\$ -	\$ -	\$ 91	\$ -
<i>DUKE UNIVERSITY</i>							
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR001803	3,093	-	-	3,093	-
<i>HUDSONALPHA FOUNDATION</i>							
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	OD027070-01	3,728	-	-	3,728	-
<i>TEXAS A&M UNIVERSITY</i>							
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR001950	(15,758)	-	-	(15,758)	-
<i>OREGON HEALTH AND SCIENCE</i>							
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR002369	(1,237)	-	-	(1,237)	-
Total CFDA 93.350			(1,415)	-	-	(1,415)	8,668
RESEARCH INFRASTRUCTURE PROGRAMS	93.351		2,343,156	-	-	2,343,156	436,021
PASS-THROUGH AWARD FROM:							
<i>UNIVERSITY OF CALIFORNIA, DAVIS</i>							
RESEARCH INFRASTRUCTURE PROGRAMS	93.351	OD023221	8,581	-	-	8,581	-
<i>UNIVERSITY OF WISCONSIN</i>							
RESEARCH INFRASTRUCTURE PROGRAMS	93.351	OD011106	50,057	-	-	50,057	-
<i>JOHNS HOPKINS UNIVERSITY</i>							
RESEARCH INFRASTRUCTURE PROGRAMS	93.351	OD026691	2,425	-	-	2,425	-
<i>HARVARD MEDICAL SCHOOL</i>							
RESEARCH INFRASTRUCTURE PROGRAMS	93.351	OD026435	131,688	-	-	131,688	-
Total CFDA 93.351			2,535,907	-	-	2,535,907	436,021
21ST CENTURY CURES ACT – BEAU BIDEN CANCER MOONSHOT	93.353		1,748,470	-	-	1,748,470	51,767
PASS-THROUGH AWARD FROM:							
<i>DANA-FARBER CANCER INSTITUTE</i>							
21ST CENTURY CURES ACT – BEAU BIDEN CANCER MOONSHOT	93.353	CA155258	56,401	-	-	56,401	-
<i>CHILDREN'S HOSPITAL OF PENNSYLVANIA</i>							
21ST CENTURY CURES ACT – BEAU BIDEN CANCER MOONSHOT	93.353	CA23568	420,234	-	-	420,234	-
<i>FRED HUTCHINSON CANCER CENTER</i>							
21ST CENTURY CURES ACT – BEAU BIDEN CANCER MOONSHOT	93.353	CA154967-09	26,760	-	-	26,760	-
<i>UNIVERSITY OF UTAH</i>							
21ST CENTURY CURES ACT – BEAU BIDEN CANCER MOONSHOT	93.353	CA224076	554,688	-	-	554,688	-
Total CFDA 93.353			2,806,553	-	-	2,806,553	51,767

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
NURSING RESEARCH	93.361		\$ 845,861	\$ -	\$ -	\$ 845,861	\$ 224,179
PASS-THROUGH AWARD FROM:							
UNIVERSITY OF MICHIGAN							
NURSING RESEARCH	93.361	NR013658-06	4,378	-	-	4,378	-
THE UNIVERSITY OF TEXAS AT AUSTIN							
NURSING RESEARCH	93.361	NR018229	2,008	-	-	2,008	-
UNIVERSITY OF IOWA							
NURSING RESEARCH	93.361	NR017610	321,576	-	-	321,576	-
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON							
NURSING RESEARCH	93.361	NR017837	45,073	-	-	45,073	-
		Total CFDA 93.361	1,218,896	-	-	1,218,896	224,179
21ST CENTURY CURES ACT – PRECISION MEDICINE INITIATIVE	93.368		1,250,798	-	-	1,250,798	328,285
CANCER CAUSE AND PREVENTION RESEARCH	93.393		6,993,455	-	-	6,993,455	2,250,972
PASS-THROUGH AWARD FROM:							
OREGON HEALTH & SCIENCE							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA217842	465,421	-	-	465,421	-
CITY OF HOPE RESEARCH INSTITUTE							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA242218	30,061	-	-	30,061	-
GEORGE WASHINGTON UNIVERSITY							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA199336	122,335	-	-	122,335	-
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA181255	12,338	-	-	12,338	-
ST JUDE CHILDREN'S RESEARCH HOSPITAL							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA225478	14,750	-	-	14,750	-
VANDERBILT UNIVERSITY							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA187079	59,294	-	-	59,294	-
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA203012	222,197	-	-	222,197	-
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA225005	27,867	-	-	27,867	-
STANFORD UNIVERSITY							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA226081	87,885	-	-	87,885	-
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA226081	8,776	-	-	8,776	-
UNIVERSITY OF SOUTHERN CALIFORNIA							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA214253	259,003	-	-	259,003	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
<i>UNIVERSITY OF MASSACHUSETTS</i>							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA207369	\$ 28,960	\$ -	\$ -	\$ 28,960	\$ -
<i>H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE</i>							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA194617	(2,295)	-	-	(2,295)	-
<i>THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER</i>							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA186566	98,867	-	-	98,867	-
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA219463	9,028	-	-	9,028	-
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA239342	16,753	-	-	16,753	-
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA181663	(8,117)	-	-	(8,117)	-
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA219896	13,849	-	-	13,849	-
<i>COLUMBIA UNIVERSITY</i>							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA199336	29,203	-	-	29,203	-
<i>THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER</i>							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA212008	125,239	-	-	125,239	-
<i>ARIZONA STATE UNIVERSITY</i>							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA237118	165,936	-	-	165,936	-
		Total CFDA 93.393	8,780,805	-	-	8,780,805	2,250,972
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		6,469,490	-	-	6,469,490	3,046,453
PASS-THROUGH AWARD FROM:							
<i>THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER</i>							
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA214263	45,626	-	-	45,626	-
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA194733	4,646	-	-	4,646	-
<i>CHILDREN'S HOSPITAL OF PENNSYLVANIA</i>							
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA193776	46,652	-	-	46,652	2,119
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA193478	1,436	-	-	1,436	-
<i>THE METHODIST RESEARCH INSTITUTE</i>							
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA211861	19,545	-	-	19,545	-
<i>FRED HUTCHINSON CANCER RESEARCH CENTER</i>							
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA214172	115,504	-	-	115,504	-
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA230144	21,822	-	-	21,822	-
<i>RICE UNIVERSITY</i>							
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA103830	(13)	-	-	(13)	-
<i>WASHINGTON UNIVERSITY</i>							
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	MC27865	28,782	-	-	28,782	-
<i>THE UNIVERSITY OF TEXAS AT AUSTIN</i>							
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA229068	68,948	-	-	68,948	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
<i>NATIONWIDE CHILDREN'S HOSPITAL (CA196173)</i>							
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA196173	\$ 5,663	\$ -	\$ -	\$ 5,663	\$ -
<i>NSABP</i>							
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA196067	104,689	-	-	104,689	-
		Total CFDA 93.394	6,932,790	-	-	6,932,790	3,048,572
CANCER TREATMENT RESEARCH	93.395		4,721,297	-	-	4,721,297	1,113,859
PASS-THROUGH AWARD FROM:							
<i>NEW YORK UNIVERSITY</i>							
CANCER TREATMENT RESEARCH	93.395	CA176502	24,481	-	-	24,481	-
<i>WASHINGTON UNIVERSITY</i>							
CANCER TREATMENT RESEARCH	93.395	CA180860	(9)	-	-	(9)	-
<i>ST JUDE CHILDREN'S RESEARCH HOSPITAL</i>							
CANCER TREATMENT RESEARCH	93.395	CA81457	76,444	-	-	76,444	-
<i>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</i>							
CANCER TREATMENT RESEARCH	93.395	CA039542	5,542	-	-	5,542	-
<i>TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER</i>							
CANCER TREATMENT RESEARCH	93.395	CA221957	84,750	-	-	84,750	-
<i>UNIVERSITY OF CALIFORNIA, LOS ANGELES</i>							
CANCER TREATMENT RESEARCH	93.395	CA121947	78,169	-	-	78,169	-
<i>DUKE UNIVERSITY</i>							
CANCER TREATMENT RESEARCH	93.395	NS096096	151,766	-	-	151,766	-
<i>THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER</i>							
CANCER TREATMENT RESEARCH	93.395	CA208535	112,757	-	-	112,757	-
CANCER TREATMENT RESEARCH	93.395	CA235620	119,191	-	-	119,191	-
<i>MEDICAL COLLEGE OF WISCONSIN</i>							
CANCER TREATMENT RESEARCH	93.395	CA215403	11,350	-	-	11,350	-
CANCER TREATMENT RESEARCH	93.395	CA232892	58,888	-	-	58,888	-
<i>NRG ONCOLOGY FOUNDATION, INC</i>							
CANCER TREATMENT RESEARCH	93.395	CA180868	2,138	-	-	2,138	-
<i>OREGON HEALTH AND SCIENCE UNIVERSITY</i>							
CANCER TREATMENT RESEARCH	93.395	CA180888	11,778	-	-	11,778	-
<i>SEATTLE CHILDREN'S RESEARCH INSTITUTE</i>							
CANCER TREATMENT RESEARCH	93.395	CA222486	129,523	-	-	129,523	-
<i>UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL</i>							
CANCER TREATMENT RESEARCH	93.395	CA218442	95,760	-	-	95,760	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
<i>CHILDREN'S HOSPITAL OF PHILADELPHIA</i>							
CANCER TREATMENT RESEARCH	93.395	CA196854	\$ 3,444	\$ -	\$ -	\$ 3,444	\$ -
CANCER TREATMENT RESEARCH	93.395	CA180884	28,790	-	-	28,790	-
CANCER TREATMENT RESEARCH	93.395	CA180886	929,951	-	-	929,951	-
CANCER TREATMENT RESEARCH	93.395	CA097452	40,175	-	-	40,175	-
CANCER TREATMENT RESEARCH	93.395	CA211996	1,564	-	-	1,564	-
CANCER TREATMENT RESEARCH	93.395	CA228823	156,924	-	-	156,924	-
CANCER TREATMENT RESEARCH	93.395	CA233249	33,011	-	-	33,011	-
CANCER TREATMENT RESEARCH	93.395	CA189955	47,400	-	-	47,400	-
		Total CFDA 93.395	6,925,084	-	-	6,925,084	1,113,859
CANCER BIOLOGY RESEARCH	93.396		10,692,307	-	-	10,692,307	367,772
PASS-THROUGH AWARD FROM:							
<i>THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER</i>							
CANCER BIOLOGY RESEARCH	93.396	CA174798	95,790	-	-	95,790	-
CANCER BIOLOGY RESEARCH	93.396	CA240526	6,859	-	-	6,859	-
CANCER BIOLOGY RESEARCH	93.396	CA184208	136,660	-	-	136,660	-
CANCER BIOLOGY RESEARCH	93.396	CA190863	10,456	-	-	10,456	-
CANCER BIOLOGY RESEARCH	93.396	CA193362	5,924	-	-	5,924	-
<i>DARTMOUTH COLLEGE</i>							
CANCER BIOLOGY RESEARCH	93.396	CA225028	9,402	-	-	9,402	-
<i>GEORGIA TECH UNIVERSITY</i>							
CANCER BIOLOGY RESEARCH	93.396	CA218664	23,111	-	-	23,111	-
<i>MOUNT SINAI SCHOOL</i>							
CANCER BIOLOGY RESEARCH	93.396	CA154947	43,000	-	-	43,000	-
<i>UNIVERSITY OF COLORADO DENVER</i>							
CANCER BIOLOGY RESEARCH	93.396	CA224867	404,274	-	-	404,274	-
<i>UNIVERSITY OF PITTSBURGH</i>							
CANCER BIOLOGY RESEARCH	93.396	CA181368	7,443	-	-	7,443	-
<i>THE UNIVERSITY OF NORTH CAROLINA</i>							
CANCER BIOLOGY RESEARCH	93.396	CA148761	165,947	-	-	165,947	-
CANCER BIOLOGY RESEARCH	93.396	CA195754	48,404	-	-	48,404	-
<i>UNIVERSITY OF NEW MEXICO</i>							
CANCER BIOLOGY RESEARCH	93.396	CA206980	109,290	-	-	109,290	-
<i>UNIVERSITY OF WASHINGTON</i>							
CANCER BIOLOGY RESEARCH	93.396	CA190378	27,672	-	-	27,672	-
		Total CFDA 93.396	11,786,539	-	-	11,786,539	367,772

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
CANCER CENTERS SUPPORT GRANTS	93.397		\$ 7,313,158	\$ -	\$ -	\$ 7,313,158	\$ 316,626
PASS-THROUGH AWARD FROM:							
<i>THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER</i>							
CANCER CENTERS SUPPORT GRANTS	93.397	CA140388	20,666	-	-	20,666	-
CANCER CENTERS SUPPORT GRANTS	93.397	CA127001	19,234	-	-	19,234	-
<i>SOUTHWEST ONCOLOGY GROUP</i>							
CANCER CENTERS SUPPORT GRANTS	93.397	CA180888	53,284	-	-	53,284	-
<i>SARCOMA ALLIANCE FOR RESEARCH COLLABORATION</i>							
CANCER CENTERS SUPPORT GRANTS	93.397	CA168512	(414)	-	-	(414)	-
<i>THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER</i>							
CANCER CENTERS SUPPORT GRANTS	93.397	CA217333	46,730	-	-	46,730	-
		Total CFDA 93.397	7,452,658	-	-	7,452,658	316,626
CANCER RESEARCH MANPOWER	93.398		2,074,927	-	-	2,074,927	-
PASS-THROUGH AWARD FROM:							
<i>RICE UNIVERSITY</i>							
CANCER RESEARCH MANPOWER	93.398	AR071258	44,755	-	-	44,755	-
CANCER RESEARCH MANPOWER	93.398	CA213994	37,660	-	-	37,660	-
CANCER RESEARCH MANPOWER	93.398	DK108541	6,554	-	-	6,554	-
CANCER RESEARCH MANPOWER	93.398	CA213878	35,706	-	-	35,706	-
		Total CFDA 93.398	2,199,602	-	-	2,199,602	-
CANCER CONTROL	93.399		494,533	-	-	494,533	-
PASS-THROUGH AWARD FROM:							
<i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON</i>							
CANCER CONTROL	93.399	CA232888	28,202	-	-	28,202	-
<i>CHILDREN'S HOSPITAL OF PHILADELPHIA</i>							
CANCER CONTROL	93.399	CA189955	43,805	-	-	43,805	-
<i>NSABP</i>							
CANCER CONTROL	93.399	CA12027	40,443	-	-	40,443	-
		Total CFDA 93.399	606,983	-	-	606,983	-
PASS-THROUGH AWARD FROM:							
<i>TIRR MEMORIAL HERMANN</i>							
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING AND REHABILITATION RESEARCH	93.433	90S15027-01	9,348	-	-	9,348	-
COVID-19 CLAIMS REIMBURSEMENT TO HEALTH CARE PROVIDERS AND FACILITIES FOR TESTING, TREATMENT AND VACCINE ADMINISTRATION FOR THE UNINSURED	93.461		-	-	389,046	389,046	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM:							
<i>TEXAS DEPARTMENT OF FAMILY AND PROTECTIVE SERVICES</i>							
TEMPORARY ASSISTANCE FOR NEEDY FAMILIES	93.558	529-16-0003-00003	\$ -	\$ -	\$ 695,561	\$ 695,561	\$ -
<i>TEXAS COUNCIL FOR DEVELOPMENTAL DISABILITIES</i>							
DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS	93.630	19111	-	-	168,539	168,539	73,882
DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS	93.630	19112	-	-	71,799	71,799	-
DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS	93.630	20211	-	-	8,429	8,429	-
DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS	93.630	20212	-	-	9,331	9,331	-
Total CFDA 93.630			-	-	258,098	258,098	73,882
CARDIOVASCULAR DISEASES RESEARCH	93.837		12,482,672	-	-	12,482,672	1,072,902
PASS-THROUGH AWARD FROM:							
<i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL087318	64,487	-	-	64,487	-
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL142704	14,420	-	-	14,420	-
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL145487	9,345	-	-	9,345	-
<i>OHIO STATE UNIVERSITY</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL134824	137,345	-	-	137,345	-
<i>UNIVERSITY OF COLORADO</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL127240	34,786	-	-	34,786	-
<i>BOSTON VA RESEARCH INSTITUTE</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL130163	1,649	-	-	1,649	-
<i>UNIVERSITY OF ARIZONA</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL136528	10,971	-	-	10,971	-
<i>EAST CAROLINA UNIVERSITY</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL142544	51,469	-	-	51,469	-
<i>JOHNS HOPKINS UNIVERSITY</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL096812	43,475	-	-	43,475	-
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL146907	80,382	-	-	80,382	-
<i>MASSACHUSETTS GENERAL HOSPITAL</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL123336	15,631	-	-	15,631	-
<i>PENNSYLVANIA STATE UNIVERSITY</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL137763-03	98,981	-	-	98,981	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
<i>UNIVERSITY OF HOUSTON</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL146745	\$ 187,172	\$ -	\$ -	\$ 187,172	\$ -
<i>UNIVERSITY OF CALIFORNIA, SAN FRANCISCO</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL126146	9,063	-	-	9,063	-
<i>UNIVERSITY OF BUFFALO</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL137558	37,062	-	-	37,062	-
<i>NEW YORK UNIVERSITY SCHOOL OF MEDICINE</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL117905	77	-	-	77	-
<i>TEXAS A&M UNIVERSITY</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL134780	76,078	-	-	76,078	-
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL146852	156,302	-	-	156,302	-
<i>EMORY UNIVERSITY</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL128566	3,615	-	-	3,615	-
<i>INDIANA UNIVERSITY</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL123767	59,165	-	-	59,165	-
<i>THE METHODIST HOSPITAL RESEARCH INSTITUTE</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL129767	75,949	-	-	75,949	-
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL115003	30	-	-	30	-
<i>UNIVERSITY OF ALABAMA AT BIRMINGHAM</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL120338	53,939	-	-	53,939	-
<i>NEW ENGLAND RESEARCH INSTITUTES, INC</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL107407	14,876	-	-	14,876	-
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL068270	(3,275)	-	-	(3,275)	-
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL135691	160,738	-	-	160,738	-
<i>RICE UNIVERSITY</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL140305	227,888	-	-	227,888	-
<i>YALE UNIVERSITY</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL141852	11,918	-	-	11,918	-
		Total CFDA 93.837	14,116,210	-	-	14,116,210	1,072,902
LUNG DISEASES RESEARCH							
PASS-THROUGH AWARD FROM:	93.838		2,824,337	-	-	2,824,337	36,527
<i>NATIONAL JEWISH MEDICAL AND RESEARCH CENTER</i>							
LUNG DISEASES RESEARCH	93.838	HL089897	81,996	-	-	81,996	-
<i>UNIVERSITY OF PITTSBURGH</i>							
LUNG DISEASES RESEARCH	93.838	HL128954	667	-	-	667	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
UNIVERSITY OF ALABAMA AT BIRMINGHAM LUNG DISEASES RESEARCH	93.838	HL133232	\$ 4,430	\$ -	\$ -	\$ 4,430	\$ -
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER LUNG DISEASES RESEARCH	93.838	HL130129	13,730	-	-	13,730	-
THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON LUNG DISEASES RESEARCH	93.838	HL145477	174,641	-	-	174,641	-
YALE UNIVERSITY LUNG DISEASES RESEARCH	93.838	HL145567	7,673	-	-	7,673	-
COPD FOUNDATION LUNG DISEASES RESEARCH	93.838	HL128954	12,972	-	-	12,972	-
VANDERBILT UNIVERSITY LUNG DISEASES RESEARCH	93.838	HL111111	3,144	-	-	3,144	-
Total CFDA 93.838			3,123,590	-	-	3,123,590	36,527
BLOOD DISEASES AND RESOURCES RESEARCH	93.839		3,135,906	-	-	3,135,906	205,051
PASS-THROUGH AWARD FROM:							
THOMAS JEFFERSON UNIVERSITY BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL128234	57,023	-	-	57,023	-
CHILDRENS HOSPITAL MEDICAL CENTER, CINCINNATI BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL133883	19,557	-	-	19,557	-
UNIVERSITY OF UTAH BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL102482	73,660	-	-	73,660	-
BOSTON CHILDREN'S HOSPITAL BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL133384	1,265	-	-	1,265	-
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL124112	107,080	-	-	107,080	-
BLOOD WORKS NORTHWEST BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL125957	35,255	-	-	35,255	-
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL152200	983	-	-	983	-
MEDICAL COLLEGE OF WISCONSIN BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL103427	(1,117)	-	-	(1,117)	-
RUTGERS UNIVERSITY BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL125804	76	-	-	76	-
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL133817	30,338	-	-	30,338	-
UNIVERSITY OF HOUSTON BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL151858	7,176	-	-	7,176	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
<i>WASHINGTON UNIVERSITY</i>							
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	GM113838	\$ 1,866	\$ -	\$ -	\$ 1,866	\$ -
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL128863	1,587	-	-	1,587	-
	Total CFDA 93.839		3,470,655	-	-	3,470,655	205,051
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846		5,103,557	-	-	5,103,557	1,482,634
PASS-THROUGH AWARD FROM:							
<i>VANDERBILT UNIVERSITY</i>							
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR072483	66,860	-	-	66,860	-
<i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON</i>							
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR075380	15,694	-	-	15,694	-
<i>CINCINNATI CHILDREN'S HOSPITAL</i>							
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR071651	65	-	-	65	-
	Total CFDA 93.846		5,186,176	-	-	5,186,176	1,482,634
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		24,552,668	-	-	24,552,668	4,830,020
PASS-THROUGH AWARD FROM:							
<i>TUFTS MEDICAL CENTER</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK098245	83	-	-	83	-
<i>UNIVERSITY OF IOWA</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK118752	150	-	-	150	-
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK108328	10,816	-	-	10,816	-
<i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK081866	(328)	-	-	(328)	-
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK116378	233,859	-	-	233,859	-
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK114235	17,660	-	-	17,660	-
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	AI055449	4,109	-	-	4,109	-
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK122708	14,702	-	-	14,702	-
<i>ARBOR RESEARCH COLLABORATIVE</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK062456	2,267	-	-	2,267	-
<i>BAYLOR RESEARCH INSTITUTE</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK117001	3,189	-	-	3,189	-
<i>CHILDREN'S NATIONAL MEDICAL CENTER</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK102561	179,079	-	-	179,079	-
<i>CEDARS-SINAI MEDICAL CENTER</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK109588	131,098	-	-	131,098	-
<i>CASE WESTERN RESERVE UNIVERSITY</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK118290	172,812	-	-	172,812	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
<i>UNIVERSITY OF UTAH</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	CA224076	\$ 53,429	\$ -	\$ -	\$ 53,429	\$ -
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK114456	32,784	-	-	32,784	-
<i>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK119200	35,002	-	-	35,002	-
<i>UNIVERSITY OF COLORADO</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK090964	6,115	-	-	6,115	-
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK072493	43,518	-	-	43,518	-
<i>UNIVERSITY OF COLORADO DENVER</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK117001	12,025	-	-	12,025	-
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK062453	434	-	-	434	-
<i>MICHIGAN STATE UNIVERSITY</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK103759	(60)	-	-	(60)	-
<i>UNIVERSITY OF MICHIGAN</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK101108	8,913	-	-	8,913	-
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK062456	13,006	-	-	13,006	-
<i>JOHNS HOPKINS UNIVERSITY</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK061730	22,459	-	-	22,459	-
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK089174	38,908	-	-	38,908	-
<i>GEORGE WASHINGTON UNIVERSITY</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK061230	256,013	-	-	256,013	-
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK098246	519,219	-	-	519,219	-
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK104845	269	-	-	269	-
<i>SAINT LOUIS UNIVERSITY</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK061718	180,777	-	-	180,777	-
<i>THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK100866	3,113	-	-	3,113	-
<i>RUTGERS UNIVERSITY</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK112365	84,613	-	-	84,613	-
<i>STATE UNIVERSITY OF NEW YORK</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK110456	796	-	-	796	-
<i>UNIVERSITY OF ARIZONA</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK106462	908	-	-	908	-
<i>SEATTLE CHILDREN'S RESEARCH</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK121224	101,805	-	-	101,805	-
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK113005	152,579	-	-	152,579	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
<i>UNIVERSITY OF MARYLAND</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK061425	\$ 64,675	\$ -	\$ -	\$ 64,675	\$ -
<i>UNIVERSITY OF CALIFORNIA, SAN DIEGO</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK097771	238,574	-	-	238,574	-
<i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK115761	193,698	-	-	193,698	-
<i>THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK108328	60,699	-	-	60,699	-
<i>VANDERBILT UNIVERSITY</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK111831	253,840	-	-	253,840	-
<i>CHILDREN'S HOSPITAL OF PHILADELPHIA</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK066174	6,203	-	-	6,203	-
<i>CHILDRENS HOSPITAL MEDICAL CENTER, CINCINNATI</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK103117	71,396	-	-	71,396	-
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK072493	47,304	-	-	47,304	-
<i>UNIVERSITY OF WASHINGTON</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK095869	11,640	-	-	11,640	-
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK092202	28,907	-	-	28,907	-
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK107436	33,080	-	-	33,080	-
<i>UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK090964	126,168	-	-	126,168	-
<i>UNIVERSITY OF HOUSTON</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK117476	37,541	-	-	37,541	-
<i>UNIVERSITY OF KENTUCKY</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK118954	27,953	-	-	27,953	-
<i>UNIVERSITY OF PENNSYLVANIA</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK102384	24,108	-	-	24,108	-
<i>THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK105585	15,742	-	-	15,742	-
<i>AMERICAN PSYCHOLOGICAL ASSOCIATION</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK118763	14,681	-	-	14,681	-
<i>UNIVERSITY OF SOUTH FLORIDA</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK106955	(90,708)	-	-	(90,708)	-
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK112243	10,414	-	-	10,414	-
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK117483	744,432	-	-	744,432	-
Total CFDA 93.847			28,809,136	-	-	28,809,136	4,830,020

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853		\$ 22,458,738	\$ -	\$ -	22,458,738	\$ 2,767,860
PASS-THROUGH AWARD FROM:							
<i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS098981	68,948	-	-	68,948	-
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS090405	101,538	-	-	101,538	-
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS103592	170,928	-	-	170,928	-
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS110806	26,677	-	-	26,677	-
<i>COLUMBIA UNIVERSITY</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS098976	505	-	-	505	-
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS078059	20,502	-	-	20,502	-
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	MS089674	2,780	-	-	2,780	-
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS073872	69,728	-	-	69,728	-
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	HD055651	264,126	-	-	264,126	-
<i>CASE WESTERN RESERVE UNIVERSITY</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS090405	(3,538)	-	-	(3,538)	-
<i>EMORY UNIVERSITY</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS51630	264,354	-	-	264,354	-
<i>UNIVERSITY OF CINCINNATI</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS095869	725	-	-	725	-
<i>VANDERBILT UNIVERSITY</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS097898	8,433	-	-	8,433	-
<i>KENNEDY KRIEGER INSTITUTE</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS098482	126,281	-	-	126,281	-
<i>NORTHWESTERN UNIVERSITY</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS108874	112,269	-	-	112,269	-
<i>TEXAS A&M UNIVERSITY</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS094535	46,793	-	-	46,793	-
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS106907	24,888	-	-	24,888	-
<i>RICE UNIVERSITY</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS099870	1,237	-	-	1,237	-
<i>UNIVERSITY OF MICHIGAN</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS099340	32,572	-	-	32,572	-
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS099046	30,074	-	-	30,074	-
<i>DUKE UNIVERSITY</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS112917	97,317	-	-	97,317	-
<i>MASSACHUSETTS GENERAL HOSPITAL</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS090259	2,722	-	-	2,722	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
<i>MAYO CLINIC</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS115198	\$ 9,708	\$ -	\$ -	\$ 9,708	\$ -
<i>UNIVERSITY OF DELAWARE</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS111310	12,718	-	-	12,718	-
<i>UNIVERSITY OF HOUSTON</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS112497	25,550	-	-	25,550	-
<i>UNIVERSITY OF MINNESOTA</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS062091	(23)	-	-	(23)	-
<i>UNIVERSITY OF WISCONSIN</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS115102	24,768	-	-	24,768	-
<i>WILLIAMS BONE MARROW TRANSPLANT HOSPITAL</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS110838	4,649	-	-	4,649	-
<i>UNIVERSITY OF CALIFORNIA, SAN FRANCISCO</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS086090	96,466	-	-	96,466	-
		Total CFDA 93.853	24,102,433	-	-	24,102,433	2,767,860
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		15,220,403	-	-	15,220,403	1,029,595
COVID-19 ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		503,818	-	-	503,818	37,616
PASS-THROUGH AWARD FROM:							
<i>VANDERBILT UNIVERSITY</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI125135	58,396	-	-	58,396	-
<i>WASHINGTON UNIVERSITY</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI077810	1,054	-	-	1,054	-
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI141716	282,722	-	-	282,722	-
<i>UNIVERSITY OF UTAH</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI125301	65,548	-	-	65,548	-
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI136963	114,997	-	-	114,997	-
<i>YALE UNIVERSITY</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI089992	47,777	-	-	47,777	-
<i>EMORY UNIVERSITY</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI148684	24,479	-	-	24,479	-
COVID-19 ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI148684	17,729	-	-	17,729	-
<i>BETH ISRAEL DEACONESS MEDICAL CENTER</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI116596	96,051	-	-	96,051	-
<i>THE UNIVERSITY OF TEXAS AT AUSTIN</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI131497	109	-	-	109	-
<i>DUKE UNIVERSITY</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI104681	42,869	-	-	42,869	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
<i>MASSACHUSETTS GENERAL HOSPITAL</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI127507	\$ 12,718	\$ -	\$ -	\$ 12,718	\$ -
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI134940	23,097	-	-	23,097	-
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI114552	19,841	-	-	19,841	-
<i>UNIVERSITY OF ALABAMA</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI027767	16,636	-	-	16,636	-
<i>THE METHODIST HOSPITAL RESEARCH INSTITUTE</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI120749	14,973	-	-	14,973	-
<i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI055449	33,553	-	-	33,553	-
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI116208	133,301	-	-	133,301	-
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	GM120011	31,552	-	-	31,552	-
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI119572	57,767	-	-	57,767	-
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI143229	75,528	-	-	75,528	-
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI141349	58,606	-	-	58,606	-
<i>COLUMBIA UNIVERSITY</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI20989	2,240	-	-	2,240	-
<i>UNIVERSITY OF MICHIGAN</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI116482	23,981	-	-	23,981	-
<i>UNIVERSITY OF CALIFORNIA, SAN FRANCISCO</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI082973	2,270	-	-	2,270	-
<i>UNIVERSITY OF CALIFORNIA, SAN DIEGO</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI069536	777,980	-	-	777,980	-
<i>UNIVERSITY OF PITTSBURGH</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI032539	131,774	-	-	131,774	-
<i>TEXAS TECH UNIVERSITY</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI135197	38,461	-	-	38,461	-
<i>TUFTS UNIVERSITY</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI121401	5,538	-	-	5,538	-
<i>UNIVERSITY OF HOUSTON</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI122418	50,317	-	-	50,317	-
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI133697	29,983	-	-	29,983	-
<i>JOHNS HOPKINS UNIVERSITY</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI068632	147,514	-	-	147,514	-
<i>GEORGE WASHINGTON UNIVERSITY</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI129789	(5,229)	-	-	(5,229)	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
<i>CHILDREN'S HOSPITAL OF BOSTON</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI084011	\$ 3,429	\$ -	\$ -	\$ 3,429	\$ -
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI108588	399,177	-	-	399,177	-
<i>NEW YORK BLOOD CENTER</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI078314	85,852	-	-	85,852	-
<i>CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI117804	6,632	-	-	6,632	-
<i>NEW YORK STATE HEALTH (AL14489101-A1)</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AL14489101	21,747	-	-	21,747	-
<i>THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI105135	71,614	-	-	71,614	-
	Total CFDA 93.855		18,746,804	-	-	18,746,804	1,067,211
BIOMEDICAL RESEARCH AND RESEARCH TRAINING							
PASS-THROUGH AWARD FROM:							
<i>UNIVERSITY OF CALIFORNIA, BERKELEY</i>							
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM063210	72,651	-	-	72,651	-
<i>NIMBIC SYSTEMS</i>							
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM095005	(74,648)	-	-	(74,648)	-
<i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON</i>							
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM120011	90,353	-	-	90,353	-
<i>STANFORD UNIVERSITY</i>							
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM103297	2,864	-	-	2,864	-
<i>SANFORD BURNHAM MEDICAL RESEARCH INSTITUTE</i>							
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM121203	216,544	-	-	216,544	-
<i>THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER</i>							
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM127332	105,327	-	-	105,327	-
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM098200	62,317	-	-	62,317	-
<i>CINCINNATI CHILDREN'S HOSPITAL</i>							
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM126943	106	-	-	106	-
<i>TEXAS A&M UNIVERSITY</i>							
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM132436	40,810	-	-	40,810	-
<i>UNIVERSITY OF MICHIGAN</i>							
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	AI150470	59,329	-	-	59,329	-
<i>UNIVERSITY OF ILLINOIS</i>							
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM115111	36,115	-	-	36,115	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
<i>COLUMBIA UNIVERSITY</i>							
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM119396	\$ 112,171	\$ -	\$ -	\$ 112,171	\$ -
<i>THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON</i>							
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM110591	73,440	-	-	73,440	-
	Total CFDA 93.859		14,195,100	-	-	14,195,100	576,221
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH							
PASS-THROUGH AWARD FROM:							
<i>ARIZONA STATE UNIVERSITY</i>							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD095380	46,934	-	-	46,934	-
<i>UNIVERSITY OF NORTH CAROLINA</i>							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD086139	6,673	-	-	6,673	-
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD089880	151,904	-	-	151,904	-
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD089881	320,541	-	-	320,541	-
<i>COLUMBIA UNIVERSITY</i>							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD055651	290,603	-	-	290,603	-
<i>CHILDREN'S RESEARCH INSTITUTE</i>							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD061221	149,924	-	-	149,924	-
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD094213	26,620	-	-	26,620	-
<i>UNIVERSITY OF ALABAMA AT BIRMINGHAM</i>							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD061222	37,420	-	-	37,420	-
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD086851	171,120	-	-	171,120	-
<i>PENNSYLVANIA STATE UNIVERSITY</i>							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD089922	12,901	-	-	12,901	-
<i>PRESIDENT AND FELLOWS OF HARVARD COLLEGE ON BEHALF OF HARVARD MEDICAL SCHOOL</i>							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD52102	671,332	-	-	671,332	-
<i>WEILL MEDICAL COLLEGE</i>							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD067244	236,831	-	-	236,831	64,353
<i>UNIVERSITY OF CALIFORNIA, LOS ANGELES</i>							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD092471	408	-	-	408	-
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD095548	29,237	-	-	29,237	-
<i>INDIANA UNIVERSITY</i>							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD090215	32,093	-	-	32,093	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
<i>UNIVERSITY OF MARYLAND</i>							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH <i>CHILDREN'S HOSPITAL MEDICAL CENTER</i>	93.865	HD068712	\$ 2,892	\$ -	\$ -	\$ 2,892	\$ -
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH <i>UNIVERSITY OF HOUSTON</i>	93.865	HD092989	23,454	-	-	23,454	-
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH <i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON</i>	93.865	HD099242	19,792	-	-	19,792	-
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH <i>UNIVERSITY OF MICHIGAN</i>	93.865	HD093660	193,748	-	-	193,748	-
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH <i>THE BRIGHAM & WOMEN'S HOSPITAL, INC</i>	93.865	HD085233	952	-	-	952	-
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HG009922	109,237	-	-	109,237	-
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD077671	46,168	-	-	46,168	-
	Total CFDA 93.865		18,339,211	-	-	18,339,211	2,305,875
AGING RESEARCH	93.866		10,481,014	-	-	10,481,014	859,079
PASS-THROUGH AWARD FROM:							
<i>EMORY UNIVERSITY</i>							
AGING RESEARCH	93.866	AG046161	85,425	-	-	85,425	-
AGING RESEARCH	93.866	AG061357	70,030	-	-	70,030	-
AGING RESEARCH	93.866	AG065187	66,102	-	-	66,102	-
<i>BOSTON UNIVERSITY</i>							
AGING RESEARCH	93.866	AG058589	97,514	-	-	97,514	-
<i>STANFORD UNIVERSITY</i>							
AGING RESEARCH	93.866	AG036695	813,949	-	-	813,949	298,560
<i>UNIVERSITY OF CALIFORNIA, SAN DIEGO</i>							
AGING RESEARCH	93.866	AG010483	60	-	-	60	-
<i>MASSACHUSETTS GENERAL HOSPITAL</i>							
AGING RESEARCH	93.866	AG064413	5,837	-	-	5,837	-
<i>OHIO STATE UNIVERSITY</i>							
AGING RESEARCH	93.866	AG058822	3,683	-	-	3,683	-
<i>RICE UNIVERSITY</i>							
AGING RESEARCH	93.866	AG062690	22,317	-	-	22,317	-
<i>TEXAS A&M UNIVERSITY</i>							
AGING RESEARCH	93.866	AG061726	19,970	-	-	19,970	-
<i>UNIVERSITY OF HOUSTON</i>							
AGING RESEARCH	93.866	AG065170	13,470	-	-	13,470	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
<i>THE UNIVERSITY OF TEXAS AT SAN ANTONIO</i>							
AGING RESEARCH	93.866	AG052409	\$ 40,716	\$ -	\$ -	\$ 40,716	\$ -
<i>UNIVERSITY OF SOUTHERN CALIFORNIA</i>							
AGING RESEARCH	93.866	AG010483	63,208	-	-	63,208	-
AGING RESEARCH	93.866	AG041845	86,994	-	-	86,994	-
AGING RESEARCH	93.866	AG024904	24,772	-	-	24,772	-
AGING RESEARCH	93.866	AG063689	563	-	-	563	-
<i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON</i>							
AGING RESEARCH	93.866	AG049506	(89)	-	-	(89)	-
AGING RESEARCH	93.866	AG058463	233,923	-	-	233,923	-
AGING RESEARCH	93.866	AG060413	35,435	-	-	35,435	-
AGING RESEARCH	93.866	AG061901	28,854	-	-	28,854	-
AGING RESEARCH	93.866	AG061646	103,279	-	-	103,279	-
		Total CFDA 93.866	12,297,026	-	-	12,297,026	1,157,639
VISION RESEARCH	93.867		9,486,336	-	-	9,486,336	1,835,432
PASS-THROUGH AWARD FROM:							
<i>EMORY UNIVERSITY</i>							
VISION RESEARCH	93.867	EY025553	(4,725)	-	-	(4,725)	-
<i>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC</i>							
VISION RESEARCH	93.867	EY11751	75,470	-	-	75,470	-
VISION RESEARCH	93.867	EY14231	115,399	-	-	115,399	-
<i>CLEVELAND CLINIC FOUNDATION</i>							
VISION RESEARCH	93.867	EY031087	21,268	-	-	21,268	-
<i>NEW YORK UNIVERSITY</i>							
VISION RESEARCH	93.867	EY026869	16,346	-	-	16,346	-
<i>TEXAS A&M UNIVERSITY</i>							
VISION RESEARCH	93.867	EY029695	101,791	-	-	101,791	-
<i>UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER</i>							
VISION RESEARCH	93.867	EY026999	10,253	-	-	10,253	-
<i>THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON</i>							
VISION RESEARCH	93.867	EY026999	121	-	-	121	-
<i>UNIVERSITY OF WASHINGTON</i>							
VISION RESEARCH	93.867	EY025181	2,654	-	-	2,654	-
		Total CFDA 93.867	9,824,913	-	-	9,824,913	1,835,432

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
MEDICAL LIBRARY ASSISTANCE	93.879		\$ 204,667	\$ -	\$ -	\$ 204,667	\$ 42,874
PASS-THROUGH AWARD FROM: <i>RICE UNIVERSITY</i>							
MEDICAL LIBRARY ASSISTANCE	93.879	LM007093	68,709	-	-	68,709	-
Total CFDA 93.879			273,376	-	-	273,376	42,874
PASS-THROUGH AWARD FROM: <i>REACH UP, INC</i>							
HEALTHY START INITIATIVE	93.926	H49MC12793	49,270	-	-	49,270	-
<i>TEXAS DEPARTMENT OF STATE HEALTH SERVICES</i>							
HIV PREVENTION ACTIVITIES_HEALTH DEPARTMENT BASED	93.940	HHS000077800010	-	-	68,032	68,032	-
PPHF GERIATRIC EDUCATION CENTERS	93.969		470,360	-	-	470,360	79,983
PRIMARY CARE MEDICINE AND DENTISTRY CLINICIAN EDUCATOR CAREER DEVELOPMENT AWARDS	93.976		89,852	-	-	89,852	-
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989		118,791	-	-	118,791	-
PASS-THROUGH AWARD FROM: <i>TEXAS DEPARTMENT OF STATE HEALTH SERVICES</i>							
MATERNAL AND CHILD HEALTH SERVICES BLOCK GRANT TO THE STATES	93.994	HHS000109600030	-	-	17,989	17,989	-
<i>THE UNIVERSITY OF TEXAS AT AUSTIN (TEXAS DEPARTMENT OF STATE HEALTH SERVICES)</i>							
MATERNAL AND CHILD HEALTH SERVICES BLOCK GRANT TO THE STATES	93.994	HHS0000115300001	-	-	114,845	114,845	-
Total CFDA 93.994			-	-	132,834	132,834	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM:							
<i>UNIVERSITY OF NEBRASKA</i>							
ADOLESCENT FAMILY LIFE DEMONSTRATION PROJECTS	93.995	75D30118C02909	\$ 58,685	\$ -	\$ -	\$ 58,685	\$ -
	93.RD	AHRQ HHS290201500002C	395	-	-	395	-
	93.RD	CDC #75D30119C05322	198,997	-	-	198,997	-
	93.RD	CDC-200-2017-95100	65,691	-	-	65,691	-
	93.RD	HHSN268201600015I	14,156	-	-	14,156	-
	93.RD	HHSN268201600033I	45,205	-	-	45,205	-
	93.RD	HHSN27200005-15-0038.B1C1.0034	8,616	-	-	8,616	-
	93.RD	HHSN27200006-14-0100.B1C1D1.0036	(6)	-	-	(6)	(6)
	93.RD	HHSN27200008-16-0017.B1C1D1.0043	31,443	-	-	31,443	-
	93.RD	HHSN27200009-15-0020	250,638	-	-	250,638	3,057
	93.RD	HHSN27200010-15-0050	(3,068)	-	-	(3,068)	-
	93.RD	HHSN27200011-15-0066	2,702	-	-	2,702	-
	93.RD	HHSN27200012-16-0075	278,151	-	-	278,151	-
	93.RD	HHSN27200014-16-0050	174,141	-	-	174,141	-
	93.RD	HHSN27200015	669,524	-	-	669,524	190,836
	93.RD	HHSN27200017	16,804	-	-	16,804	-
	93.RD	HHSN2720013-16-0057.C1D1.00 58	1,185,820	-	-	1,185,820	1,059,326
	93.RD	HHSN272201300015I	248,708	-	-	248,708	-
	93.RD	HHSN2722013-14	442,346	-	-	442,346	397,837
	93.RD	NHLBI HHSN268201600015I	164,311	-	-	164,311	-
	93.RD	NIAID HHSN272201700013I	(894)	-	-	(894)	-
	93.RD	NICHD HHSN275201500002C	13,672	-	-	13,672	13,215
	93.RD	NIH 75N91019P00756	2,558	-	-	2,558	-
	93.RD	NIH 75N93019P01211	81,763	-	-	81,763	-
	93.RD	N01-A1-80002	(21,974)	-	-	(21,974)	-
	93.RD	75N93019F00071	(4,383)	-	-	(4,383)	-
	93.RD	75N93019F00131	249,758	-	-	249,758	-
	93.RD	75N93019F00132	608,256	-	-	608,256	-
PASS-THROUGH AWARD FROM:							
<i>ATLANTA RESEARCH AND EDUCATION FOUNDATION</i>							
	93.RD	CDC 75D30119C04211	590,319	-	-	590,319	-
<i>BOSTON UNIVERSITY</i>							
	93.RD	HHSN261201500026C	63,047	-	-	63,047	-
<i>CHILDREN'S HOSPITAL LOS ANGELES (CA209-9JY)</i>							
	93.RD	CA209-9JY	180	-	-	180	-
<i>DUKE UNIVERSITY</i>							
	93.RD	HHSN271201200006I	668	-	-	668	-
<i>DUKE UNIVERSITY</i>							
	93.RD	HHSN275201000003I	64,088	-	-	64,088	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
EASTERN VIRGINIA MEDICAL SCHOOL	93.RD	CDC-200-2016-91451	\$ 4,257	\$ -	\$ -	4,257	\$ -
HEALTH RESEARCH AND EDUCATION TRUST	93.RD	HHSA290201000025I	(14,125)	-	-	(14,125)	-
HENNEPIN RESEARCH INSTITUTE	93.RD	75N-94019C00006	7,274	-	-	7,274	-
INTELLIGENCE ADVANCED RESEARCH PROJECTS ACTIVITY	93.RD	D16PC00003	2,632,874	-	-	2,632,874	830,896
INTELLIGENCE ADVANCED RESEARCH PROJECTS ACTIVITY	93.RD	2019-19071900001	328,873	-	-	328,873	-
MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH	93.RD	W19031	9,712	-	-	9,712	-
MEDSTAR RESEARCH INSTITUTE	93.RD	HHSP233201500022I	178,745	-	-	178,745	-
NATIONAL MARROW DONOR PROGRAM	93.RD	NUMBER 1702	1,544	-	-	1,544	-
NATIONAL MARROW DONOR PROGRAM	93.RD	NUMBER 1801	1,544	-	-	1,544	-
NATIONAL MARROW DONOR PROGRAM	93.RD	NUMBER 1802	830	-	-	830	-
NEW ENGLAND RESEARCH INSTITUTE	93.RD	HHSN-2682012000	4,650	-	-	4,650	-
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	93.RD	HHSN268201700001I	(2,400)	-	-	(2,400)	-
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	93.RD	75D30118C02646	18,220	-	-	18,220	-
UNIVERSITY OF ALABAMA AT BIRMINGHAM	93.RD	HHSN272201600017C	17,475	-	-	17,475	-
UNIVERSITY OF ALABAMA AT BIRMINGHAM	93.RD	HHSN272201100035C	2,019	-	-	2,019	-
UNIVERSITY OF COLORADO DENVER	93.RD	HHSF223201610046C	25	-	-	25	-
UNIVERSITY OF MICHIGAN	93.RD	HHSN268201800002I	130,883	-	-	130,883	-
UNIVERSITY OF NORTH CAROLINA	93.RD	HHSN268201700001I	290,320	-	-	290,320	-
UNIVERSITY OF NORTH CAROLINA	93.RD	HHSN26800003	111,997	-	-	111,997	-
UNIVERSITY OF SOUTH FLORIDA	93.RD	NIDDK-TRIALNET	10,490	-	-	10,490	-
TOTAL DEPARTMENT OF HEALTH AND HUMAN SERVICES			281,057,495	543,011	5,970,572	287,571,078	35,008,429
EXECUTIVE OFFICE OF THE PRESIDENT							
PASS-THROUGH AWARD FROM:							
UNIVERSITY OF BALTIMORE							
RESEARCH AND DATA ANALYSIS	95.007	G1999ONDCP06A	227,224	-	-	227,224	-
TOTAL EXECUTIVE OFFICE OF THE PRESIDENT			227,224	-	-	227,224	-
AGENCY FOR INTERNATIONAL DEVELOPMENT							
USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	98.001		-	-	1,277	1,277	-
TOTAL AGENCY FOR INTERNATIONAL DEVELOPMENT			-	-	1,277	1,277	-
TOTAL EXPENDITURES OF FEDERAL AWARDS			\$ 333,738,123	\$ 20,887,313	\$ 6,442,933	\$ 361,068,369	\$ 51,758,307

See accompanying notes to schedule of expenditures of federal awards and schedule of expenditures of state awards.

Baylor College of Medicine
Schedule of Expenditures of State Awards
Year Ended June 30, 2020

Program Description	Pass-Through Entity/Other Identifying Number	Total Expenditures	Amounts Provided to Subrecipients
State of Texas: Direct & Pass-through			
CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS			
<i>DIRECT AWARD:</i>			
	DP150064	\$ (21,347)	\$ -
	DP150083	(1,351)	-
	PP160079	294,429	237,836
	PP160089	322,016	146,371
	PP160122	334,266	97,188
	PP170036	367,389	-
	PP170094	505,901	418,446
	PP180016	549,850	147,104
	PP190051	118,091	-
	R1313-YR	(377)	-
	RP120685	19,540	-
	RP120732	(1,823)	-
	RP130256	3,236	-
	RP130368	(5,420)	-
	RP130573	(31,113)	-
	RP150032	177,001	130,963
	RP150081	935	-
	RP150129	115,833	-
	RP150334	136,642	-
	RP150587	1,777,885	793,418
	RP150648	1,423,210	-
	RP160022	398,928	-
	RP160035	234,968	-
	RP160097	845,769	-
	RP160192	(911)	-
	RP160283	725,233	-
	RP160345	5,538	-

Baylor College of Medicine

Schedule of Expenditures of State Awards (continued)

Program Description	Pass-Through Entity/Other Identifying Number	Total Expenditures	Amounts Provided to Subrecipients
State of Texas: Direct & Pass-through (continued) CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS (continued) <i>DIRECT AWARD (continued):</i>			
	RP160451	\$ 287	\$ -
	RP160462	192,190	-
	RP160771	788,899	228,203
	RP160805	1,528,198	-
	RP170005	989,263	-
	RP170071	301,986	69,415
	RP170074	298,434	-
	RP170169	420,461	302,238
	RP170172	256,099	117,636
	RP170295	211,695	-
	RP170387	302,786	-
	RP170488	187,545	-
	RP170500	355,955	-
	RP170675	40,831	14,241
	RP170691	1,055,579	-
	RP180177	186,685	-
	RP180196	239,198	-
	RP180672	477,981	-
	RP180674	1,171,134	101,438
	RP180755	53,418	14,240
	RP180785	1,362,586	-
	RP180810	86,720	-
	RP180844	63,746	-
	RP180851	76,689	-
	RP190002	265,182	34,726
	RP190067	520,113	-
	RP190104	40,487	-
	RP190132	288,930	-
	RP190160	258,960	19,176

Baylor College of Medicine

Schedule of Expenditures of State Awards (continued)

Program Description	Pass-Through Entity/Other Identifying Number	Total Expenditures	Amounts Provided to Subrecipients
State of Texas: Direct & Pass-through (continued)			
CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS (continued)			
<i>DIRECT AWARD (continued):</i>			
	RP190279	\$ 207,292	\$ 74,242
	RP190398	227,013	-
	RP190497	51,512	-
	RP190522	283,195	150,829
	RP190567	70,682	-
	RP190602	2,366,936	-
	RP190641	197,207	-
	RP200402	6,218	-
	RP200443	40,528	-
	RR140033	500,699	-
	RR150005	115,449	-
	RR150009	140,343	-
	RR150093	132,818	-
	RR150106	412,873	-
	RR160009	593,865	-
	RR160027	906,221	-
	RR170023	388,361	46,531
	RR170024	284,349	-
	RR170036	105,596	-
	RR170039	292,395	-
	RR170048	1,164,688	-
	RR180061	384,896	-
	RR180072	444,511	-
	RR190043	797,548	-
	RR190054	309,179	-
	RR200005	179,436	-
		30,920,165	3,144,241

Baylor College of Medicine

Schedule of Expenditures of State Awards (continued)

Program Description	Pass-Through Entity/Other Identifying Number	Total Expenditures	Amounts Provided to Subrecipients
State of Texas: Direct & Pass-through (continued)			
CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS (continued)			
PASS-THROUGH AWARD FROM:			
<i>TEXAS A&M UNIVERSITY HEALTH SCIENCE CENTER</i>			
	DP150086	\$ (10,935)	\$ -
	RP150578	81,988	-
	RP170719	302,319	-
	RP170653	(19,983)	-
		353,389	-
<i>THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER</i>			
	PR190192	96,762	-
	RP160237	14,193	-
	RP170366	3,159	-
	RP180166	55,611	-
	RP180313	6,586	-
	RP180712	265,818	-
	RP190252	85,408	-
		527,537	-
<i>THE METHODIST HOSPITAL RESEARCH INSTITUTE</i>			
	RP160384	46,590	-
	RP180394	115,977	-
	RP150611	(1,287)	-
		161,280	-
<i>THE UNIVERSITY OF TEXAS AT AUSTIN</i>			
	RP170427	21,332	-
	RP180073	17,860	-
		39,192	-
<i>THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON</i>			
	PP190023	44,634	-
	RP170593	161,068	-
		205,702	-

Baylor College of Medicine

Schedule of Expenditures of State Awards (continued)

Program Description	Pass-Through Entity/Other Identifying Number	Total Expenditures	Amounts Provided to Subrecipients
State of Texas: Direct & Pass-through (continued)			
CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS (continued)			
PASS-THROUGH AWARD FROM (continued):			
<i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON</i>			
	PP140183		
	PP170046	\$ 20,919	\$ -
	PP180086	9,716	-
	PP180089	53,738	-
	RP170330	63,688	-
	RP190019	56,712	-
		204,773	-
 <i>THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER</i>			
	RP180457	40,205	-
TOTAL CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS		32,452,243	3,144,241
 TEXAS COUNCIL ON ALZHEIMER'S DISEASE AND RELATED DISORDERS			
	TX COUNCIL ALZHEIMER/DISORDERS	228,032	-
TOTAL TEXAS COUNCIL ON ALZHEIMER'S DISEASE AND RELATED DISORDERS		228,032	-
 TOBACCO SETTLEMENT FUNDS			
	BCM TOBACCO ENDOWMENT	1,487,973	-
	STATE MANAGED TOBACCO FUNDS	2,309,275	-
TOTAL TOBACCO SETTLEMENT FUNDS		3,797,248	-
 JOINT ADMISSIONS MEDICAL PROGRAM (JAMP) COUNCIL			
	EVALUATION & ACCOUNTABILITY EVALUATION PROGRAM	55,880	-
	MEDICAL SCHOOL PROGRAM	173,341	-
	SPECIAL PROJECTS FOR PROGRAM INITIATIVES	12,781	-
TOTAL JOINT ADMISSIONS MEDICAL PROGRAM COUNCIL		242,002	-

Baylor College of Medicine

Schedule of Expenditures of State Awards (continued)

Program Description	Pass-Through Entity/Other Identifying Number	Total Expenditures	Amounts Provided to Subrecipients
State of Texas: Direct & Pass-through (continued)			
TEXAS HIGHER EDUCATION COORDINATING BOARD			
FAMILY PRACTICE RESIDENCY PROGRAM	THECB AGREEMENT NUMBER 21004	\$ 50,991	\$ -
FAMILY PRACTICE RESIDENCY PROGRAM	THECB AGREEMENT NUMBER 22455	83,233	-
		<u>134,224</u>	-
GRADUATE MEDICAL EDUCATION – RESIDENT SUPPORT			
	THECB # 21818	467,328	-
	MISSION SUPPORT	7,017,260	-
GME EXPANSION GRANT	THECB AGREEMENT NUMBER 19733	126,893	-
GME EXPANSION GRANT	THECB AGREEMENT NUMBER 19734/20573	984,117	-
GME EXPANSION GRANT	THECB AGREEMENT NUMBER 19735/20595	137,069	-
GME EXPANSION GRANT	THECB AGREEMENT NUMBER 19736/20596	858,119	-
GME EXPANSION GRANT	THECB AGREEMENT NUMBER 19905/20689	1,094,031	-
		<u>10,684,817</u>	-
UNDERGRADUATE MEDICAL EDUCATION PROGRAM			
	THECB AGREEMENT NUMBER 21816	36,690,503	-
	MISSION SUPPORT	22,937,771	-
		<u>59,628,274</u>	-
EMERGENCY AND TRAUMA CARE EDUCATION PARTNERSHIP PROGRAM			
EMERGENCY AND TRAUMA CARE EDUCATION PARTNERSHIP PROGRAM	THECB AGREEMENT NUMBER 19802	116,818	-
EMERGENCY AND TRAUMA CARE EDUCATION PARTNERSHIP PROGRAM	THECB AGREEMENT NUMBER 19815/21776	74,740	-
		<u>191,558</u>	-
AUTISM GRANT PROGRAM – PARENT DIRECTED TREATMENT			
AUTISM GRANT PROGRAM – PARENT DIRECTED TREATMENT	THECB AGREEMENT NUMBER 20701/20463	214,197	-
	THECB AGREEMENT NUMBER 21270	100,290	-
PASS-THROUGH AWARD FROM:			
<i>THE UNIVERSITY OF TEXAS AT SAN ANTONIO</i>			
AUTISM GRANT PROGRAM	BMS20226	45,377	-
		<u>359,864</u>	-

Baylor College of Medicine

Schedule of Expenditures of State Awards (continued)

Program Description	Pass-Through Entity/Other Identifying Number	Total Expenditures	Amounts Provided to Subrecipients
State of Texas: Direct & Pass-through (continued)			
TEXAS HIGHER EDUCATION COORDINATING BOARD (continued)			
PASS-THROUGH AWARD FROM (continued):			
<i>THE UNIVERSITY OF TEXAS SYSTEM – TEXAS CHILD MENTAL HEALTH CARE CONSORTIUM</i>			
CHILD PSYCHIATRY ACCESS NETWORK	THECB 2020-310	\$ 128,184	\$ –
TEXAS CHILD HEALTH ACCESS THROUGH TELEMEDICINE	THECB 2020-310	186,095	–
		<u>314,279</u>	<u>–</u>
TOTAL TEXAS HIGHER EDUCATION COORDINATING BOARD		71,313,016	–
TEXAS DEPARTMENT OF FAMILY & PROTECTIVE SERVICES			
PASS-THROUGH AWARD FROM:			
<i>HARRIS COUNTY</i>			
COMMUNITY-BASED SERVICES FOR ADJUDICATED YOUTH	HARRIS/CPS-JUV PROB/BELAY	143,982	–
	QIC INITIATIVE	4,566	–
		<u>148,548</u>	<u>–</u>
TOTAL TEXAS DEPARTMENT OF FAMILY & PROTECTIVE SERVICES		148,548	–
TEXAS DEPARTMENT OF STATE HEALTH SERVICES			
TB PEDIATRIC SERVICES	2016-048247 PO#417866	(1,928)	–
DEPARTMENT OF HEALTH AND HUMAN SERVICES	537-18-0098-00001	4,364	–
		<u>2,436</u>	<u>–</u>
PASS-THROUGH FROM TEXAS DEPARTMENT OF STATE HEALTH SERVICES			
<i>HARRIS HEALTH</i>			
HIV/STD Program	HIV PERI-NATAL TRANSMISSION PREVENTION FY19	131,979	–
HIV/STD Program	HIV PERI-NATAL TRANSMISSION PREVENTION FY20	73,167	–
HIV/STD Program	HIV PREVENTION	108,342	–
		<u>313,488</u>	<u>–</u>
<i>THE UNIVERSITY OF TEXAS AT AUSTIN</i>			
LONE STAR STROKE CLINICAL TRIAL NETWORK	LONE STAR STROKE CLINICAL TRIAL NETWORK	520,856	–

Baylor College of Medicine

Schedule of Expenditures of State Awards (continued)

Program Description	Pass-Through Entity/Other Identifying Number	Total Expenditures	Amounts Provided to Subrecipients
State of Texas: Direct & Pass-through (continued)			
TEXAS DEPARTMENT OF STATE HEALTH SERVICES (continued)			
PASS-THROUGH FROM TEXAS DEPARTMENT OF STATE HEALTH SERVICES			
<i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT TYLER</i>			
SAFE BABIES PROJECT	24307170	\$ 330,392	\$ -
TOTAL TEXAS DEPARTMENT OF STATE HEALTH SERVICES		1,167,172	-
TEXAS HEALTH AND HUMAN SERVICES COMMISSION			
HEALTHY TEXAS WOMEN/FAMILY PLANNING GRANT PROGRAM CLUSTER			
HEALTHY TEXAS WOMEN'S GRANT PROGRAM	529-16-0132-00020	880,576	-
FAMILY PLANNING GRANT PROGRAM	529-16-0102-00011	3,275,370	-
TOTAL HEALTHY TEXAS WOMEN/FAMILY PLANNING GRANT PROGRAM CLUSTER		4,155,946	-
TOTAL TEXAS HEALTH AND HUMAN SERVICES COMMISSION		4,155,946	-
TOTAL EXPENDITURES OF STATE AWARDS		\$ 113,504,207	\$ 3,144,241

See accompanying notes to schedule of expenditures of federal awards and schedule of expenditures of state awards.

Baylor College of Medicine

Notes to Schedule of Expenditures of Federal Awards and Schedule of Expenditures of State Awards

Year Ended June 30, 2020

1. Basis of Presentation

The accompanying schedule of expenditures of federal awards and schedule of expenditures of state awards (the Schedules) present a summary of the financial activities of Baylor College of Medicine (the College) for the year ended June 30, 2020, which have been funded by the federal and state governments. The information in the Schedules is presented in accordance with the requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) and the *State of Texas Single Audit Circular*. Because the Schedules present only federal and state expenditure activities of the College, they are not intended to and do not present the financial position, changes in net assets, or cash flows of the College as a whole.

2. Summary of Significant Accounting Policies

The Schedules have been prepared on a modified accrual basis of accounting and include all expenditures of federal and state awards, direct and pass-through, received by the College from federal and state grantor agencies. Direct costs are charged to sponsored agreements on a cash basis except for salaries and fringe benefits that are charged on an accrual basis. Indirect costs are expensed against sponsored agreements at the close of the month in which the direct costs are charged, and, therefore are a combination of modified accrual and cash basis accounting. Federal and state awards are deemed to be expended when the College incurs the expenses. Such expenditures are recognized following the cost principles contained in the Uniform Guidance or the State of Texas *Uniform Grant Management Standards* (UGMS), as applicable, wherein certain types of expenditures are not allowable or are limited as to reimbursement. Federal and state direct programs and pass-through programs are presented by federal or state department and, where applicable, the funding agency within the department and the pass-through entity.

The College did not elect to use the 10-percent de minimis indirect cost rate as allowed under the Uniform Guidance.

Baylor College of Medicine

Notes to Schedule of Expenditures of Federal Awards and
Schedule of Expenditures of State Awards (continued)

3. Administered Federal Loan Programs

Outstanding loans under administered federal loan programs as of June 30, 2020, were as follows:

	CFDA	Outstanding Balance June 30, 2020
Federal Perkins Loan Program	84.038	\$ 2,324,070
Health Professions Student Loans, Including Primary Care Loans/Loans for Disadvantaged Students (Health Professions Student Loans)	93.342	457,371

Total disbursements for student financial assistance loan programs administered by the College on behalf of the Department of Health and Human Services and the Department of Education for the fiscal year ended June 30, 2020, are identified below.

	CFDA	FY 2020 Disbursements
Federal Perkins Loan Program	84.038	\$ —
Health Professions Student Loans	93.342	—

4. Federal Direct Student Loans Program

The College participated in the Federal Direct Student Loans Program (CFDA 84.268), including Unsubsidized Stafford Loans and PLUS Loans. The College was not the recipient of the funds. The programs are considered as a component of the student financial assistance cluster. Loan disbursements under the programs for the year ended June 30, 2020, totaled \$16,857,027.

Baylor College of Medicine

Notes to Schedule of Expenditures of Federal Awards and Schedule of Expenditures of State Awards (continued)

5. State Awards Classification

The expenditures of state awards presented in this Schedule were identified pursuant to the definition of state awards promulgated in the *State of Texas Single Audit Circular*. State awards include all state financial assistance and state cost-reimbursement contracts received directly from state awarding agencies or indirectly from pass-through entities. State awards do not include state financial assistance or state cost-reimbursement contracts received directly or indirectly under the terms of other federal awards, or federal awards as defined in the Uniform Guidance, either passed through a state agency or received directly from a federal agency. The state awards have been classified by program according to award objective and state awarding agency.

6. Texas Higher Education Coordinating Board Undergraduate Medical Education Program

Significant Estimates

Direct instructional expenses were estimated using the College's educational metrics system. The educational metrics system contains data about faculty participation in undergraduate medical student teaching. Faculty participation is measured in time-based units, by educational service and academic department. Direct instructional expenses are estimated using the average faculty compensation and related estimated benefits expense for each time-based unit of undergraduate medical student education provided by the College's faculty.

Expenses for academic support and student services were identified as expended based on the portion of expenses estimated as having been consumed in support of undergraduate medical student education.

Facilities and Administration Cost Rate

The College has applied the instruction component of its approved federal facilities and administration cost rate to Coordinating Board contract expenses. The approved rate was 35%.

7. Donated Personal Protective Equipment [Unaudited]

The College received \$24,748 of donated personal protective equipment (PPE) purchased with federal assistance funds for the year ended June 30, 2020. PPE is valued based on fair market value at the time of receipt.

Baylor College of Medicine

Schedule of Findings and Questioned Costs

Year Ended June 30, 2020

Section I – Summary of Auditor’s Results

Financial Statements

Type of auditor’s report issued on whether the financial statements audited were prepared in accordance with GAAP:

Unmodified

Internal control over financial reporting:

Material weakness(es) identified? Yes X No

Significant deficiency(ies) identified? Yes X None reported

Noncompliance material to financial statements noted? Yes X No

Federal Awards

Internal control over major federal programs:

Material weakness(es) identified? Yes X No

Significant deficiency(ies) identified? Yes X None reported

Type of auditor’s report issued on compliance for major federal programs:

Unmodified

Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)?

 Yes X No

Baylor College of Medicine

Schedule of Findings and Questioned Costs (continued)

Section I – Summary of Auditors’ Results (continued)

State Awards

Internal control over major state programs:

Material weakness(es) identified? _____ Yes X No

Significant deficiency(ies) identified? _____ Yes X None reported

Type of auditor’s report issued on compliance for major state programs: _____ Unmodified

Any audit findings disclosed that are required to be reported in accordance with Section .510(a) of the *State of Texas Single Audit Circular*? _____ Yes X No

<u>Assistance Listing Number(s)</u>	<u>Name of Federal or State Program or Cluster</u>
-------------------------------------	--

Identification of major federal programs: Various CFDA	Research and Development Cluster
---	----------------------------------

Identification of major state programs: No CFDA No CFDA	Cancer Prevention & Research Institute of Texas Healthy Texas Women/Family Planning Grant Program Cluster
---	---

Dollar threshold to distinguish between Type A and Type B federal programs _____ \$3,000,000

Dollar threshold to distinguish between Type A and Type B state programs _____ \$3,000,000

Auditee qualified as low-risk auditee? X Yes _____ No

Baylor College of Medicine

Schedule of Findings and Questioned Costs (continued)

Section II – Financial Statement Findings

No findings were noted.

Section III – Federal Award Findings and Questioned Costs

No findings were noted.

Section IV – State Award Findings and Questioned Costs

No findings were noted.

EY | Building a better working world

EY exists to build a better working world, helping to create long-term value for clients, people and society and build trust in the capital markets.

Enabled by data and technology, diverse EY teams in over 150 countries provide trust through assurance and help clients grow, transform and operate.

Working across assurance, consulting, law, strategy, tax and transactions, EY teams ask better questions to find new answers for the complex issues facing our world today.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit ey.com.

Ernst & Young LLP is a client-serving member firm of Ernst & Young Global Limited operating in the US.

© 2021 Ernst & Young LLP.
All Rights Reserved.

ey.com